



FEDERAL REGISTER

Vol. 84

Tuesday,

No. 19

January 29, 2019

Pages 437–466

OFFICE OF THE FEDERAL REGISTER



The **FEDERAL REGISTER** (ISSN 0097-6326) is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Publishing Office, is the exclusive distributor of the official edition. Periodicals postage is paid at Washington, DC.

The **FEDERAL REGISTER** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see www.federalregister.gov.

The seal of the National Archives and Records Administration authenticates the **Federal Register** as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the **Federal Register** shall be judicially noticed.

The **Federal Register** is published in paper and on 24x microfiche. It is also available online at no charge at www.govinfo.gov, a service of the U.S. Government Publishing Office.

The online edition of the **Federal Register** is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6:00 a.m. each day the **Federal Register** is published and includes both text and graphics from Volume 1, 1 (March 14, 1936) forward. For more information, contact the GPO Customer Contact Center, U.S. Government Publishing Office. Phone 202-512-1800 or 866-512-1800 (toll free). E-mail, gpocusthelp.com.

The annual subscription price for the **Federal Register** paper edition is \$860 plus postage, or \$929, for a combined **Federal Register**, **Federal Register** Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the **Federal Register** including the **Federal Register** Index and LSA is \$330, plus postage. Six month subscriptions are available for one-half the annual rate. The prevailing postal rates will be applied to orders according to the delivery method requested. The price of a single copy of the daily **Federal Register**, including postage, is based on the number of pages: \$11 for an issue containing less than 200 pages; \$22 for an issue containing 200 to 400 pages; and \$33 for an issue containing more than 400 pages. Single issues of the microfiche edition may be purchased for \$3 per copy, including postage. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: U.S. Government Publishing Office—New Orders, P.O. Box 979050, St. Louis, MO 63197-9000; or call toll free 1-866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, see bookstore.gpo.gov.

There are no restrictions on the republication of material appearing in the **Federal Register**.

How To Cite This Publication: Use the volume number and the page number. Example: 84 FR 12345.

Postmaster: Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Publishing Office, Washington, DC 20402, along with the entire mailing label from the last issue received.

SUBSCRIPTIONS AND COPIES

PUBLIC

Subscriptions:

Paper or fiche 202-512-1800
Assistance with public subscriptions 202-512-1806

General online information 202-512-1530; 1-888-293-6498

Single copies/back copies:

Paper or fiche 202-512-1800
Assistance with public single copies 1-866-512-1800
(Toll-Free)

FEDERAL AGENCIES

Subscriptions:

Assistance with Federal agency subscriptions:

Email FRSubscriptions@nara.gov
Phone 202-741-6000

The Federal Register Printing Savings Act of 2017 (Pub. L. 115-120) placed restrictions on distribution of official printed copies of the daily **Federal Register** to members of Congress and Federal offices. Under this Act, the Director of the Government Publishing Office may not provide printed copies of the daily **Federal Register** unless a Member or other Federal office requests a specific issue or a subscription to the print edition. For more information on how to subscribe use the following website link: <https://www.gpo.gov/frsubs>.



Contents

Federal Register

Vol. 84, No. 19

Tuesday, January 29, 2019

Centers for Disease Control and Prevention

NOTICES

Agency Information Collection Activities; Proposals, Submissions, and Approvals, 455–458

Drug Enforcement Administration

RULES

Schedules of Controlled Substances:
Placement of MAB-CHMINACA in Schedule I, 444–448

Education Department

NOTICES

Agency Information Collection Activities; Proposals, Submissions, and Approvals:
Evaluation of Preschool Special Education Practices Efficacy Study, 454–455
Eligibility Designations and Applications for Waiving Eligibility Requirements:
Programs under the Higher Education Act, 451–454

Energy Department

RULES

Energy Conservation Program:
Standards for Certain External Power Supplies, 437–443

PROPOSED RULES

Energy Conservation Program:
Energy Conservation Standards for Residential Furnaces and Commercial Water Heaters, 449–450

Federal Aviation Administration

RULES

Airworthiness Directives:
The Boeing Company Airplanes, 443–444

Health and Human Services Department

See Centers for Disease Control and Prevention
See National Institutes of Health

Homeland Security Department

NOTICES

Meetings:
Homeland Security Advisory Council; Cancellation, 466

Justice Department

See Drug Enforcement Administration

National Institutes of Health

NOTICES

Meetings:
Center for Scientific Review, 458–464
National Cancer Institute, 458–459
National Center for Complementary and Integrative Health, 462
National Heart, Lung, and Blood Institute, 461–463
National Institute of Allergy and Infectious Diseases, 460
National Institute of Arthritis and Musculoskeletal and Skin Diseases, 460
National Institute of Mental Health, 463
National Institute on Drug Abuse, 461–462
Requirements and Registration for Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge, 464–466

Transportation Department

See Federal Aviation Administration

Reader Aids

Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, and notice of recently enacted public laws.

To subscribe to the Federal Register Table of Contents electronic mailing list, go to <https://public.govdelivery.com/accounts/USGPOOFR/subscriber/new>, enter your e-mail address, then follow the instructions to join, leave, or manage your subscription.

CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

10 CFR

429.....	437
430.....	437

Proposed Rules:

430.....	449
431.....	449

14 CFR

39.....	443
---------	-----

21 CFR

1308.....	444
-----------	-----

Rules and Regulations

Federal Register

Vol. 84, No. 19

Tuesday, January 29, 2019

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents.

DEPARTMENT OF ENERGY

10 CFR Parts 429 and 430

[EERE-2019-BT-STD-0001]

RIN 1904-AE23

Energy Conservation Program: Energy Conservation Standards for Certain External Power Supplies

AGENCY: Office of Energy Efficiency and Renewable Energy, Department of Energy.

ACTION: Final rule; technical amendments.

SUMMARY: The Department of Energy (DOE) is publishing this final rule to amend its current regulations regarding certain aspects related to its energy conservation standards and scope of coverage for external power supplies. The contents of these technical amendments correspond with provisions enacted by Congress through the Power and Security Systems Act and EPS Improvement Act. DOE is also correcting a misprint related to a table detailing certain statutorily-prescribed requirements.

DATES: The effective date of this rule is January 29, 2019.

ADDRESSES: The docket, which includes Federal Register notices and other supporting documents/materials, is available for review at <http://www.regulations.gov>. All documents in the docket are listed in the <http://www.regulations.gov> index.

A link to the docket web page can be found at <http://www.regulations.gov>. The docket web page will contain simple instructions on how to access all documents, including public comments, in the docket.

FOR FURTHER INFORMATION CONTACT: Mr. Jeremy Domm, U.S. Department of Energy, Office of Energy Efficiency and Renewable Energy, Building Technologies Office, EE-5B, 1000 Independence Avenue SW, Washington, DC 20585-0121. Telephone: (202) 586-

9870. Email:

ApplianceStandardsQuestions@ee.doe.gov.

Mr. Michael Kido, U.S. Department of Energy, Office of the General Counsel, GC-33, 1000 Independence Avenue SW, Washington, DC 20585-0121. Telephone: (202) 586-8145. Email: michael.kido@hq.doe.gov.

For further information on how to review the docket contact the Appliance and Equipment Standards Program staff at (202) 287-1445 or by email: ApplianceStandardsQuestions@ee.doe.gov.

SUPPLEMENTARY INFORMATION:

Table of Contents

- I. Background
- II. Summary of This Action
- III. Final Action
- IV. Impacts
 - A. Power and Security Systems Act Cost Impacts
 - B. External Power Supply Improvement Act of 2017 Cost Impacts
- V. Procedural Requirements
 - A. Review Under Executive Order 12866, "Regulatory Planning and Review"
 - B. Review Under Executive Orders 13771 and 13777
 - C. Review Under the Regulatory Flexibility Act
 - D. Review Under the Paperwork Reduction Act of 1995
 - E. Review Under the National Environmental Policy Act of 1969
 - F. Review Under Executive Order 13132, "Federalism"
 - G. Review Under Executive Order 12988, "Civil Justice Reform"
 - H. Review Under the Unfunded Mandates Reform Act of 1995
 - I. Review Under the Treasury and General Government Appropriations Act, 1999
 - J. Review Under Executive Order 12630, "Governmental Actions and Interference With Constitutionally Protected Property Rights"
 - K. Review Under the Treasury and General Government Appropriations Act, 2001
 - L. Review Under Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use"
 - M. Congressional Notification
- VI. Approval of the Office of the Secretary

I. Background

The Power and Security Systems ("PASS") Act, Public Law 115-78 (November 2, 2017) and the EPS Improvement Act of 2017 (Pub. L. 115-115) both amended certain aspects of the Energy Policy and Conservation Act, as amended ("EPCA"), Public Law 94-

163. These recent amendments modified, among other things, the applicability of certain compliance deadlines related to external power supplies ("EPSs") used in certain applications and aspects of the definition for external power supplies. Pursuant to the PASS Act, DOE is modifying its regulations regarding the non-application of no-load mode requirements by amending the text to explicitly state that the no-load requirements do not apply to certain external power supplies manufactured prior to the effective date of any amendment from a final rule published by DOE under 42 U.S.C. 6295(u)(3)(D)(ii). That provision requires DOE to publish a final rule by July 1, 2021, that determines whether the standards in effect should be amended. If DOE amends those standards, the amended standards would apply to products manufactured starting on July 1, 2023. With respect to the EPS Improvement Act, DOE is amending its external power supply definition by excluding certain categories of products—namely, those power supply circuits, drivers, or devices that are "designed exclusively to be connected to, and power" light-emitting diodes ("LEDs") providing illumination, organic light-emitting diodes ("OLEDs") providing illumination; or ceiling fans using direct current motors. See 42 U.S.C. 6291(36)(A)(ii) (as amended by the EPS Improvement Act).

This document codifies in the Code of Federal Regulations ("CFR") these revisions to EPCA. Additionally, to ensure consistency throughout its regulatory framework, DOE is also correcting a cross-reference in the certification requirements for external power supplies that appear in the CFR and making a correction regarding the description of the standards currently in place for Class A external power supplies. See 10 CFR 429.37(b)(2)(iv) and 10 CFR 430.32(w)(1)(i). The rule corrects the internal cross-reference in 10 CFR 429.37(b)(2)(iv) to refer to § 430.32(w)(5), which relates to certification requirements involving external power supplies that are exempt from the no-load mode requirements. The Class A external power supply-related correction addresses missing text describing the maximum energy consumption limit for Class A external

power supplies with a nameplate output of not more than 250 watts by including (as already provided in the statute) a separate internal header denoting the “No-Load Mode” required for these types of external power supplies and adding internal column headers for the specified “Nameplate Output” and “Maximum Consumption” level. (EPCA does not have an efficiency requirement for Class A external power supplies with a no-load nameplate output exceeding 250 watts.) Without including this statutorily-prescribed explanatory text, the current value of 0.5 watts included in the current table listing the active mode energy efficiency/energy usage requirements may be unclear. This clarifying change would comport with the active mode requirements with the requirements already found in 42 U.S.C. 6295(u)(3)(A).

II. Summary of This Action

DOE is placing the amendments described in the previous section (*i.e.*, definitional changes, modified dates, and clarification) into 10 CFR part 430 (“Energy Conservation Program for Certain Consumer Products”). In addition, DOE is prescribing modifications to 10 CFR part 429 (“Certification, Compliance, and Enforcement for Consumer Products and Commercial and Industrial Equipment”). As a result of these provisions, power supply circuits, drivers, and devices designed exclusively to be connected to and power three key categories of products—(1) light-emitting diodes providing illumination; (2) organic light-emitting diodes providing illumination; or (3) ceiling fans using direct current motors—are excluded from the external power supply definition. Additionally, the no-load mode standards will not apply to certain external power supplies certified to DOE as being designed to be connected to a security or life safety alarm and surveillance system component until the effective date of any amended standards that DOE publishes through a final rule in July 2021 regarding whether to amend the external power supply standards in place. Finally, DOE’s current table listing the active mode standards for Class A external power supplies will match the statutory text.

III. Final Action

DOE has determined, pursuant to 5 U.S.C. 553(b)(B), that prior notice and an opportunity for public comment on this final rule are unnecessary. This rule inserts into the CFR, for the benefit of the public, the revised definitional

provisions and timelines related to external power supplies prescribed by the PASS Act and EPS Improvement Act, corrects an internal cross-reference in DOE’s certification regulations, and makes a clarification to bring the current regulatory text into conformity with the relevant statutory provision. DOE, therefore, finds that good cause exists to waive prior notice and an opportunity to comment for this rulemaking. For the same reasons, DOE, pursuant to 5 U.S.C. 553(d)(3), finds that good cause exists for making this final rule effective upon publication in the **Federal Register**.

IV. Impacts

DOE has determined that the PASS Act and the EPS Improvement Act of 2017 would result in costs savings to manufacturers of EPSs, LEDs, and ceiling fans. Consistent with OMB Circular A–4 and E.O. 13771, these changes would yield annualized cost savings of approximately \$2.14 and \$2.62 million (2016\$), discounted at 3 and 7 percent, respectively.

A. Power and Security Systems Act Cost Impacts

As described in section II, the PASS Act delays by six years a requirement that DOE determine whether to amend the standards in effect (*i.e.*, from 2015 to 2021) and that the compliance date for any amended standards that DOE may decide to set be delayed from 2017 to 2023. Prior to the PASS Act, DOE was required to complete energy conservation standards for EPSs in 2015 that would have become effective in 2017. Due to the PASS Act, DOE is now required to complete energy conservation standards for EPSs by 2021 that will become effective in 2023. This change, assuming that DOE decided to amend the current standards, would result in cost savings for EPS manufacturers. DOE estimated anticipated conversion costs for EPS manufacturers to comply with future amended EPS energy conservation standards and calculated the cost savings of delaying those estimated conversion costs by six years (*i.e.*, from occurring in the years leading up to 2023 as opposed to in the years leading up to 2017).

DOE published estimated conversion costs for the adopted EPS energy conservation standards and for efficiency levels higher than the adopted standards in the February 2014 Energy Conservation Standards (“ECS”) Final Rule for EPSs. 79 FR 7846, 7901–7904 (February 10, 2014). As part of the February 2014 ECS Final Rule for EPSs, DOE adopted energy conservation standards at TSL 2 and estimated that

EPS manufacturers would have to spend approximately \$43.4 million (2012\$) in conversion costs to comply with standards set at TSL 2, or \$46.0 million in 2016\$. Additionally, DOE estimated conversion costs of more stringent standards. As part of that rulemaking DOE estimated that conversion costs at TSL 3, one TSL higher than the adopted standards, would be approximately \$45.2 million (2012\$), or \$47.9 million in 2016\$.

Based on these costs, DOE estimates conversion costs of future amended EPS energy conservation standards could be approximately \$1.9 million in 2016\$. This delay of conversion costs by six years is calculated as cost savings to EPS manufacturers. DOE then calculated the net present value of delaying approximately \$1.9 million in conversion costs by six years (leading up to 2023 instead of leading up to 2017).

B. External Power Supply Improvement Act of 2017 Cost Impacts

As described in section II, the EPS Improvement Act of 2017 excludes certain devices that would otherwise be considered as EPSs from the EPS definition when they are used in LEDs providing illumination, OLEDs providing illumination, and ceiling fans using direct current motors from the EPS energy conservation standards. This change results in cost savings for LED, OLED, ceiling fan, and EPS manufacturers since these devices will no longer be required to meet the current energy conservation standards for EPSs. As a result, manufacturers of these devices will no longer need to redesign any existing EPS models that may have failed to meet the current EPS standards. Manufacturers also are not required to test and certify any products exempt from the EPS definition when introducing them into the market in the future.

DOE estimated the number of LED, OLED, and ceiling fan models that would be affected by this statutory change because manufacturers would no longer need to redesign them to accommodate the EPS standards. DOE also used data from the February 2014 ECS Final Rule for EPSs and data from DOE’s Compliance Certification Database to estimate the average EPS revenue per model to be approximately \$126,000 in 2016\$.¹ DOE then estimated

¹ DOE calculated there were 9,027 EPS models certified in DOE’s Compliance Certification Database as of March 26, 2018 (<https://www.regulations.doe.gov/certification-data>).

The Government Regulatory Impact Model (“GRIM”) published as part of the February 2014 ECS Final Rule (<https://www.regulations.gov/>

the per model capital conversion costs and per model product conversion costs to be approximately \$10,600 and \$9,600 respectively.² DOE then calculated the estimated percentage of EPS models that need to be converted to meet the February 2014 ECS Final Rule for EPSs for the product class based on the 18W AC-DC, Basic Voltage representative unit to be 90.2 percent.³ Lastly, DOE estimated that there would be approximately 752 LED and OLED models and 131 ceiling fans models using these EPSs.⁴ Therefore, DOE estimated that manufacturers would have had to spend approximately \$13.7 million in conversion costs for EPSs used in LEDs and OLEDs⁵ and an additional \$2.4 million in conversion costs for EPSs used in ceiling fans with direct current motors.⁶

In addition to conversion costs avoided, manufacturers will not incur ongoing testing and certification costs when new models falling within the scope of the statutory definitional

docket?D=EERE-2008-BT-STD-0005) estimated the annual EPS revenue for TSL 2, the adopted TSL, was approximately \$1.076 billion (2012\$) in the year 2018, which is approximately \$1.140 billion in 2016\$.

² DOE estimated that EPS manufacturers spend approximately 4.2 percent of annual revenue on capital expenditures and approximately 3.8 percent of annual revenue on research and development (taken from the published GRIM, located <https://www.regulations.gov/docket?D=EERE-2008-BT-STD-0005>). Therefore, DOE estimated the annual per model capital expenditures of an EPS model to be approximately \$5,300 ($\$126,255 \times 4.2\%$) and the annual per model research and development costs of an EPS model to be approximately \$4,800 ($\$126,255 \times 3.8\%$). Lastly, as part of the February 2014 ECS Final Rule for EPSs, DOE estimated that EPS manufacturers would spend an amount equal to the per model capital expenditures and per model research and development each year over the two-year EPS conversion period on capital conversion costs and product conversion costs respectively to comply with amended energy conservation standards for EPSs.

³ DOE assumed that the vast majority of LED, OLED, and ceiling fan EPSs would fall in this product class.

⁴ Estimates for the number of LED and OLED models using EPSs come from Navigant Consulting's lighting database used in support of the General Services Lamps energy conservation rulemaking (81 FR 14528). Estimates for the number of ceiling fan models using EPSs come from DOE's Compliance Certification Database for ceiling fans (<https://www.regulations.doe.gov/certification-data>) checked on March 26, 2018.

⁵ The number of LED and OLED models using EPSs (757) multiplied by the percentage of models that would have been required to be converted to meet the current EPS standards (90.2 percent) multiplied by the per EPS model conversion costs (\$20,200, a combination of capital and product conversion costs).

⁶ The number of ceiling fan models using EPSs (131) multiplied by the percentage of models that would have been required to be converted to meet the current EPS standards (90.2 percent) multiplied by the per EPS model conversion costs (\$20,200, a combination of capital and product conversion costs).

changes are introduced into the market. DOE used the estimated testing time per EPS model published in the August 2015 TP Final Rule for EPSs 80 FR 51424 (August 25, 2015) and an average wage rate based on data from the Bureau of Labor Statistics and U.S. Census Bureau's Annual Survey of Manufacturers⁷ to calculate total testing costs absent the adoption of the EPS Improvement Act of 2017. Based on these estimates, DOE estimated a per model cost of approximately \$154 for manufacturers to conduct testing to comply with the current EPS test procedure.

DOE also estimated the production design cycle of EPSs used in LEDs and OLEDs and of EPSs used in ceiling fans. DOE used these estimates and the per model testing costs to calculate the average annual testing cost of EPSs used in LEDs and OLEDs, estimated at approximately \$58,000, and the average annual testing cost of EPSs used in ceiling fans with direct current motors, estimated at approximately \$5,700, absent the adoption of the EPS Improvement Act of 2017.

In addition to testing costs avoided, DOE calculated annual certification costs avoided by not having to certify the energy efficiency performance of those devices that are no longer considered as EPSs when used in LEDs, OLEDs, and ceiling fans with direct current motors using the DOE's EPS test procedure. DOE estimated the number of LED, OLED, and ceiling fan manufacturers producing products using these now excluded devices. DOE also estimated the annual certification burden of these manufacturers to introduce new models every year. DOE estimated annual certification costs of approximately \$700,000 for these devices when used in LEDs or OLEDs, and annual certification costs of approximately \$945,000 for these devices when used in ceiling fans with direct current motors absent the adoption of the EPS Improvement Act of 2017.

⁷ Wage rate is based on the mean hourly wage rate of Electrical and Electronics Engineering Technicians, May 2016 (<https://www.bls.gov/oes/current/oes173023.htm>).

Total benefits ratio is based on data from the U.S. Census Bureau's 2016 Annual Survey of Manufacturers, using Annual Payroll and Total Fringe Benefits values specific to NAICS code 335999 (All Other Miscellaneous Electrical Equipment and Component Manufacturing). <https://factfinder.census.gov/faces/nav/jsf/pages/searchresults.xhtml?refresh=t>.

V. Procedural Requirements

A. Review Under Executive Order 12866, "Regulatory Planning and Review"

This final rule is a "significant regulatory action" under the criteria set out in section 3(f) of Executive Order 12866, "Regulatory Planning and Review." 58 FR 51735 (October 4, 1993). Accordingly, this action was subject to review by the Office of Information and Regulatory Affairs ("OIRA") in the Office of Management and Budget ("OMB").

B. Review Under Executive Orders 13771 and 13777

On January 30, 2017, the President issued Executive Order 13771, "Reducing Regulation and Controlling Regulatory Costs." That Order stated the policy of the executive branch is to be prudent and financially responsible in the expenditure of funds, from both public and private sources. The Order stated it is essential to manage the costs associated with the governmental imposition of private expenditures required to comply with Federal regulations. This final rule is expected to be an E.O. 13771 deregulatory action.

Additionally, on February 24, 2017, the President issued Executive Order 13777, "Enforcing the Regulatory Reform Agenda." The Order required the head of each agency designate an agency official as its Regulatory Reform Officer (RRO). Each RRO oversees the implementation of regulatory reform initiatives and policies to ensure that agencies effectively carry out regulatory reforms, consistent with applicable law. Further, E.O. 13777 requires the establishment of a regulatory task force at each agency. The regulatory task force is required to make recommendations to the agency head regarding the repeal, replacement, or modification of existing regulations, consistent with applicable law. At a minimum, each regulatory reform task force must attempt to identify regulations that:

- (i) Eliminate jobs, or inhibit job creation;
- (ii) Are outdated, unnecessary, or ineffective;
- (iii) Impose costs that exceed benefits;
- (iv) Create a serious inconsistency or otherwise interfere with regulatory reform initiatives and policies;
- (v) Are inconsistent with the requirements of Information Quality Act, or the guidance issued pursuant to that Act, in particular those regulations that rely in whole or in part on data, information, or methods that are not publicly available or that are

insufficiently transparent to meet the standard for reproducibility; or
 (vi) Derive from or implement Executive Orders or other Presidential directives that have been subsequently rescinded or substantially modified.
 The PASS Act and the EPS Improvement Act of 2017 delay DOE

consideration of standards and exclude certain power supplies from the regulations for EPSs. This rule incorporates the provisions of these acts into the CFR. The resulting cost savings are due to ongoing avoided testing costs and certification costs for excluded power supplies; the interest on upfront

conversion costs delayed by the PASS Act from 2017 to 2023; and one-time avoided conversion costs for excluded power supplies. Excluded power supplies include EPSs used in LEDs, OLEDs, and ceiling fans with direct current motors.

TABLE V.1—ANNUALIZED COST SAVINGS BY SOURCE AND ANALYTICAL TIME HORIZON

Cost savings	Source	Time horizon	Cost savings (millions 2016\$, discounted in perpetuity at 7%)
Avoided Testing Costs	EPS Improvement Act	Perpetual	(\$0.06)
Avoided Certification Costs	EPS Improvement Act	Perpetual	(1.54)
Delayed Conversion Costs	PASS Act	2017–2022	(0.04)
Excluded EPS Conversion Costs	EPS Improvement Act	One-time (2018)	(0.98)

DOE concludes that this final rule is consistent with the directives set forth in these executive orders. Assuming a 7

percent discount rate, the final rule yields annualized cost savings of approximately \$2.62 million (2016\$).

Therefore, this final rule is an Executive Order 13771 deregulatory action.

TABLE V.2—SUMMARY OF COST SAVINGS FOR THE PASS ACT AND THE EPS IMPROVEMENT ACT OF 2017

Category	Present value (million 2016\$)	Discount rate (percent)
PASS Act Cost Savings	(0.6)	7
EPS Improvement Act of 2017 Cost Savings	(36.9)	7
Total Net Cost Impact	(37.5)	7

TABLE V.3—SUMMARY OF ANNUALIZED COST IMPACTS FOR THE PASS ACT AND THE EPS IMPROVEMENT ACT OF 2017

Category	Annual value (million 2016\$)	Discount rate (percent)
PASS Act Annualized Cost Savings	(0.04)	7
EPS Improvement Act of 2017 Annualized Cost Savings	(2.58)	7
Total Net Annualized Cost Impact	(2.62)	7

C. Review Under the Regulatory Flexibility Act

The Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*) requires preparation of an initial regulatory flexibility analysis for any rule that by law must be proposed for public comment, unless the agency certifies that the rule, if promulgated, will not have a significant economic impact on a substantial number of small entities. As required by Executive Order 13272, “Proper Consideration of Small Entities in Agency Rulemaking,” 67 FR 53461 (August 16, 2002), DOE published procedures and policies on February 19, 2003, to ensure that the potential impacts of its rules on small entities are properly considered during the rulemaking process. 68 FR 7990. The Department has made its procedures and policies available on the Office of General Counsel’s website: <http://energy.gov/gc/office-general-counsel>. This rule revises the Code of Federal

Regulations to incorporate, without substantive change, statutorily-imposed definitional changes affecting coverage under current energy conservation standards, applicable timelines related to certain rulemaking requirements, and related provisions prescribed by Public Law 115–78 and Public Law 115–115, along with a separate correction to reflect the current language found in the statute. Because this is a technical amendment for which a general notice of proposed rulemaking is not required, the Regulatory Flexibility Act does not apply to this rulemaking.

D. Review Under the Paperwork Reduction Act of 1995

This rulemaking imposes no new information or record keeping requirements. Accordingly, Office of Management and Budget clearance is not required under the Paperwork Reduction Act. (44 U.S.C. 3501 *et seq.*)

E. Review Under the National Environmental Policy Act of 1969

In this rule, DOE is incorporating requirements prescribed by the PASS Act and EPS Improvement Act and preexisting statutory language. DOE has determined that this rule falls into a class of actions that are categorically excluded from review under the National Environmental Policy Act of 1969 (42 U.S.C. 4321 *et seq.*) and DOE’s implementing regulations at 10 CFR part 1021. Specifically, this rule is strictly procedural and, therefore, would not result in any environmental impacts. Thus, this rulemaking is covered by Categorical Exclusion A6 under 10 CFR part 1021, subpart D, which applies to procedural rulemakings. Accordingly, neither an environmental assessment nor an environmental impact statement is required.

F. Review Under Executive Order 13132, "Federalism"

Executive Order 13132, "Federalism," 64 FR 43255 (August 4, 1999), imposes certain requirements on agencies formulating and implementing policies or regulations that preempt State law or that have federalism implications. The Executive Order requires agencies to examine the constitutional and statutory authority supporting any action that would limit the policymaking discretion of the States and to carefully assess the necessity for such actions. The Executive Order also requires agencies to have an accountable process to ensure meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications. On March 14, 2000, DOE published a statement of policy describing the intergovernmental consultation process it will follow in the development of such regulations. 65 FR 13735. EPCA governs and prescribes Federal preemption of State regulations as to energy conservation for the products that are the subject of this final rule. States can petition DOE for exemption from such preemption to the extent, and based on criteria, set forth in EPCA. (42 U.S.C. 6297) No further action is required by Executive Order 13132.

G. Review Under Executive Order 12988, "Civil Justice Reform"

With respect to the review of existing regulations and the promulgation of new regulations, section 3(a) of Executive Order 12988, "Civil Justice Reform," 61 FR 4729 (February 7, 1996), imposes on Federal agencies the general duty to adhere to the following requirements: (1) Eliminate drafting errors and ambiguity; (2) write regulations to minimize litigation; and (3) provide a clear legal standard for affected conduct rather than a general standard and promote simplification and burden reduction. Section 3(b) of Executive Order 12988 specifically requires that Executive agencies make every reasonable effort to ensure that the regulation: (1) Clearly specifies the preemptive effect, if any; (2) clearly specifies any effect on existing Federal law or regulation; (3) provides a clear legal standard for affected conduct while promoting simplification and burden reduction; (4) specifies the retroactive effect, if any; (5) adequately defines key terms; and (6) addresses other important issues affecting clarity and general draftsmanship under any guidelines issued by the Attorney General. Section 3(c) of Executive Order 12988 requires Executive agencies to

review regulations in light of applicable standards in section 3(a) and section 3(b) to determine whether they are met or it is unreasonable to meet one or more of them. DOE has completed the required review and determined that, to the extent permitted by law, this final rule meets the relevant standards of Executive Order 12988.

H. Review Under the Unfunded Mandates Reform Act of 1995

Title II of the Unfunded Mandates Reform Act of 1995 (UMRA) requires each Federal agency to assess the effects of Federal regulatory actions on State, local, and Tribal governments and the private sector. (Pub. L. 104-4, sec. 201 (codified at 2 U.S.C. 1531). For a proposed regulatory action likely to result in a rule that may cause the expenditure by State, local, and Tribal governments, in the aggregate, or by the private sector of \$100 million or more in any one year (adjusted annually for inflation), section 202 of UMRA requires a Federal agency to publish a written statement that estimates the resulting costs, benefits, and other effects on the national economy. (2 U.S.C. 1532(a), (b)) The UMRA also requires a Federal agency to develop an effective process to permit timely input by elected officers of State, local, and Tribal governments on a proposed "significant intergovernmental mandate," and requires an agency plan for giving notice and opportunity for timely input to potentially affected small governments before establishing any requirements that might significantly or uniquely affect small governments. On March 18, 1997, DOE published a statement of policy on its process for intergovernmental consultation under UMRA (62 FR 12820) (also available at <http://www.gc.doe.gov>). This final rule contains neither an intergovernmental mandate nor a mandate that may result in the expenditure of \$100 million or more in any year, so these requirements under the Unfunded Mandates Reform Act do not apply.

I. Review Under the Treasury and General Government Appropriations Act, 1999

Section 654 of the Treasury and General Government Appropriations Act, 1999 (Pub. L. 105-277) requires Federal agencies to issue a Family Policymaking Assessment for any rule that may affect family well-being. This final rule would not have any impact on the autonomy or integrity of the family as an institution. Accordingly, DOE has concluded that it is not necessary to prepare a Family Policymaking Assessment.

J. Review Under Executive Order 12630, "Governmental Actions and Interference With Constitutionally Protected Property Rights"

The Department has determined, under Executive Order 12630, "Governmental Actions and Interference with Constitutionally Protected Property Rights," 53 FR 8859 (March 18, 1988), that this rule would not result in any takings which might require compensation under the Fifth Amendment to the United States Constitution.

K. Review Under the Treasury and General Government Appropriations Act, 2001

Section 515 of the Treasury and General Government Appropriations Act, 2001 (44 U.S.C. 3516, note) provides for agencies to review most disseminations of information to the public under guidelines established by each agency pursuant to general guidelines issued by OMB. OMB's guidelines were published at 67 FR 8452 (February 22, 2002), and DOE's guidelines were published at 67 FR 62446 (October 7, 2002). DOE has reviewed this final rule under the OMB and DOE guidelines and has concluded that it is consistent with applicable policies in those guidelines.

L. Review Under Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use"

Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use," 66 FR 28355 (May 22, 2001), requires Federal agencies to prepare and submit to the Office of Information and Regulatory Affairs (OIRA), Office of Management and Budget, a Statement of Energy Effects for any proposed significant energy action. A "significant energy action" is defined as any action by an agency that promulgates or is expected to lead to promulgation of a final rule, and that: (1) Is a significant regulatory action under Executive Order 12866, or any successor order; and (2) is likely to have a significant adverse effect on the supply, distribution, or use of energy, or (3) is designated by the Administrator of OIRA as a significant energy action. For any proposed significant energy action, the agency must give a detailed statement of any adverse effects on energy supply, distribution, or use should the proposal be implemented, and of reasonable alternatives to the action and their expected benefits on energy supply, distribution, and use.

This final rule, which incorporates recently-enacted statutory provisions into DOE's regulations and makes specific corrections in conformity with the current statutory text, would not have a significant adverse effect on the supply, distribution, or use of energy and, therefore, is not a significant energy action. Accordingly, DOE has not prepared a Statement of Energy Effects.

M. Congressional Notification

As required by 5 U.S.C. 801, DOE will report to Congress on the promulgation of this rule prior to its effective date. The report will state that it has been determined that the rule is not a "major rule" as defined by 5 U.S.C. 804(2).

VI. Approval of the Office of the Secretary

The Secretary of Energy has approved publication of this final rule.

List of Subjects

10 CFR Part 429

Administrative practice and procedure, Confidential business information, Energy conservation, Household appliances, and Reporting and recordkeeping requirements.

10 CFR Part 430

Administrative practice and procedure, Confidential business information, Energy conservation, Household appliances, Incorporation by reference, and Small businesses.

Signed in Washington, DC, on January 18, 2019.

Daniel R. Simmons,

Assistant Secretary, Energy Efficiency and Renewable Energy.

For the reasons set forth in the preamble, DOE hereby amends chapter

II, subchapter D, of title 10 of the Code of Federal Regulations as set forth below:

PART 429—CERTIFICATION, COMPLIANCE, AND ENFORCEMENT FOR CONSUMER PRODUCTS AND COMMERCIAL AND INDUSTRIAL EQUIPMENT

■ 1. The authority citation for part 429 continues to read as follows:

Authority: 42 U.S.C. 6291–6317; 28 U.S.C. 2461 note.

■ 2. Section 429.37 is amended by revising paragraph (b)(2)(iv) to read as follows:

§ 429.37 External power supplies.

* * * * *

(b) * * *

(2) * * *

(iv) External power supplies that are exempt from no-load mode requirements under § 430.32(w)(5) of this chapter: A statement that the product is designed to be connected to a security or life safety alarm or surveillance system component, the average active-mode efficiency as a percentage (%), the nameplate output power in watts (W), and if missing from the nameplate, the certification report must also include the output current in amperes (A) of the basic model or the output current in amperes (A) of the highest- and lowest-voltage models within the external power supply design family.

* * * * *

PART 430—ENERGY CONSERVATION PROGRAM FOR CONSUMER PRODUCTS

■ 3. The authority citation for part 430 continues to read as follows:

Authority: 42 U.S.C. 6291–6309; 28 U.S.C. 2461 note.

■ 4. Section 430.2 is amended by revising the definition for "External power supply" to read as follows:

§ 430.2 Definitions.

* * * * *

External power supply means an external power supply circuit that is used to convert household electric current into DC current or lower-voltage AC current to operate a consumer product. However, the term does not include a power supply circuit, driver, or device that is designed exclusively to be connected to, and power—

(1) Light-emitting diodes providing illumination;

(2) Organic light-emitting diodes providing illumination; or

(3) Ceiling fans using direct current motors.

* * * * *

■ 5. Section 430.32 is amended by revising paragraph (w)(1)(i) and paragraph (w)(5) introductory text to read as follows:

§ 430.32 Energy and water conservation standards and their effective dates.

* * * * *

(w) External power supplies. (1)(i) Except as provided in paragraphs (w)(2) and (5) of this section, all class A external power supplies manufactured on or after July 1, 2008, shall meet the following standards:

Active mode

Nameplate output	Required efficiency (decimal equivalent of a percentage)
Less than 1 watt	0.5 times the Nameplate output.
From 1 watt to not more than 51 watts	The sum of 0.09 times the Natural Logarithm of the Nameplate Output and 0.5.
Greater than 51 watts	0.85.

No-load mode

Nameplate output	Maximum consumption
Not more than 250 watts	0.5 watts.

* * * * *

(5) *Non-application of no-load mode requirements.* The no-load mode energy efficiency standards established in paragraph (w)(1) of this section shall not apply to an external power supply that—

* * * * *

[FR Doc. 2019-00228 Filed 1-28-19; 8:45 am]

BILLING CODE 6450-01-P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2018-1066; Product Identifier 2018-NM-176-AD; Amendment 39-19540; AD 2019-01-01]

RIN 2120-AA64

Airworthiness Directives; The Boeing Company Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule; correction.

SUMMARY: The FAA is correcting an airworthiness directive (AD) that published in the *Federal Register*. That AD applies to The Boeing Company Model 787-8 airplanes powered by Rolls-Royce plc (RR) Trent 1000-A (including -A/01 and -A/01A), Trent 1000-AE (including -AE/01A), Trent 1000-C (including -C/01 and -C/01A), Trent 1000-CE (including -CE/01A), Trent 1000-D (including -D/01 and -D/01A), Trent 1000-E (including -E/01 and -E/01A), Trent 1000-G (including -G/01 and -G/01A), and Trent 1000-H (including -H/01 and H/01A) turbofan engines. As published, a document referenced in the regulatory text was incorrectly identified. This document corrects that error. In all other respects, the original document remains the same.

DATES: This correction is effective February 4, 2019.

ADDRESSES:

Examining the AD Docket

You may examine the AD docket on the internet at <http://www.regulations.gov>; or in person at the Docket Management Facility between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this AD, the regulatory evaluation, any comments received, and other information. The address for Docket Operations (phone: 800-647-5527) is Docket Management Facility, U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140,

1200 New Jersey Avenue SE, Washington, DC 20590.

FOR FURTHER INFORMATION CONTACT: Rebel Nichols, Aerospace Engineer, Propulsion Section, FAA, Seattle ACO Branch, 2200 South 216th St., Des Moines, WA 98198; phone and fax: 206-231-3556; email: Rebel.Nichols@faa.gov.

SUPPLEMENTARY INFORMATION: As published, Airworthiness Directive 2019-01-01, Amendment 39-19540 (84 FR 129, January 18, 2019) (“AD 2019-01-01”), requires revising the airplane flight manual (AFM) to limit extended operations (ETOPS) for The Boeing Company Model 787-8 airplanes powered by RR Trent 1000-A (including -A/01 and -A/01A), Trent 1000-AE (including -AE/01A), Trent 1000-C (including -C/01 and -C/01A), Trent 1000-CE (including -CE/01A), Trent 1000-D (including -D/01 and -D/01A), Trent 1000-E (including -E/01 and -E/01A), Trent 1000-G (including -G/01 and -G/01A), and Trent 1000-H (including -H/01 and H/01A) turbofan engines.

Need for the Correction

As published, a document specified in the regulatory text is incorrect. Specifically, a service bulletin that is referenced in figure 1 to paragraph (g) of AD 2019-01-01 was incorrectly identified as Rolls Royce Non Modification Service Bulletin Trent 1000 “72-AK132.” The correct number is “72-K132.” Service bulletin “72-AK132” does not exist, and therefore, operators cannot directly comply with the AD requirement that refers to that service bulletin.

Correction of Publication

The error appeared in figure 1 to paragraph (g) of AD 2019-01-01. Although no other part of the preamble or regulatory information has been corrected, we are publishing the entire rule in the *Federal Register*.

The effective date of this AD remains February 4, 2019.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.

Adoption of the Correction

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration amends part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

■ 1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Corrected]

■ 2. The FAA amends § 39.13 by adding the following new airworthiness directive (AD):

2019-01-01 The Boeing Company:
Amendment 39-19540; Docket No. FAA-2018-1066; Product Identifier 2018-NM-176-AD.

(a) Effective Date

This AD is effective February 4, 2019.

(b) Affected ADs

None.

(c) Applicability

This AD applies to The Boeing Company Model 787-8 airplanes, certificated in any category, powered by Rolls-Royce plc (RR) Trent 1000-A (including -A/01 and -A/01A), Trent 1000-AE (including -AE/01A), Trent 1000-C (including -C/01 and -C/01A), Trent 1000-CE (including -CE/01A), Trent 1000-D (including -D/01 and -D/01A), Trent 1000-E (including -E/01 and -E/01A), Trent 1000-G (including -G/01 and -G/01A), and Trent 1000-H (including -H/01 and H/01A) turbofan engines.

(d) Subject

Air Transport Association (ATA) of America Code 71, Power plant.

(e) Unsafe Condition

This AD was prompted by a report from the engine manufacturer indicating that after an engine failure, prolonged operation at high thrust settings on the remaining engine during an extended-operation (ETOPS) diversion may result in failure of the remaining engine before the diversion can be safely completed. We are issuing this AD to address unrecoverable thrust loss on both engines, which could lead to a forced landing.

(f) Compliance

Comply with this AD within the compliance times specified, unless already done.

(g) Revision of Limitations Chapter in Airplane Flight Manual (AFM)

Within 7 days after the effective date of this AD, revise the Certificate Limitations chapter of the applicable Boeing AFM Engine Appendix by incorporating the information in figure 1 to paragraph (g) of this AD. This may be accomplished by inserting a copy of this AD into the AFM. When information identical to that in figure 1 to paragraph (g) of this AD has been included in the Certificate Limitations chapter of the general revisions of the AFM, the general revisions may be inserted into the AFM, and the copy of this AD may be removed from the AFM.

Note 1 to paragraph (g) of this AD: The Boeing AFM for the aircraft affected by this

AD is required to be furnished with the aircraft, per 14 CFR 25.1581. Further,

operators of the aircraft affected by this AD must operate in accordance with the

limitations specified in the AFM, per 14 CFR 91.9.

Figure 1 to paragraph (g) of this AD – AFM Certificate Limitations

Engine Appendix - Certificate Limitations

(Required by AD 2019-01-01)

ETOPS

For 787-8 airplanes equipped with at least one Rolls Royce Trent 1000-A (including -A/01 and -A/01A), Trent 1000-AE (including -AE/01A), Trent 1000-C (including -C/01 and -C/01A), Trent 1000-CE (including -CE/01A), Trent 1000-D (including -D/01 and -D/01A), Trent 1000-E (including -E/01 and -E/01A), Trent 1000-G (including -G/01 and -G/01A), and Trent 1000-H (including -H/01 and -H/01A) engine that has greater than 1,000 total accumulated engine cycles on the intermediate pressure compressor (IPC) Rotor 1 or Rotor 2 blades

- since new or
- since the replacement of blades in accordance with the instructions of Part B or C in Rolls Royce Non Modification Service Bulletin Trent 1000 72-K132 Original Issue or later authority-approved revision.

The following limitations apply:

- Planned maximum diversion time for single engine driftdown must not exceed 180 minutes, except that a planned maximum diversion time up to 207 minutes is allowed only under the provision of Title 14 Code of Federal Regulations, part 121, Appendix P, Section I, paragraph (h).

(h) Alternative Methods of Compliance (AMOCs)

(1) The Manager, Seattle ACO Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the certification office, send it to the attention of the person identified in paragraph (i) of this AD. Information may be emailed to: *9-ANM-Seattle-ACO-AMOC-Requests@faa.gov*.

(2) Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local flight standards district office/certificate holding district office.

(3) An AMOC that provides an acceptable level of safety may be used for any repair, modification, or alteration required by this AD if it is approved by the Boeing Commercial Airplanes Organization Designation Authorization (ODA) that has been authorized by the Manager, Seattle ACO Branch, to make those findings. To be approved, the repair method, modification deviation, or alteration deviation must meet the certification basis of the airplane, and the approval must specifically refer to this AD.

(i) Related Information

For more information about this AD, contact Rebel Nichols, Aerospace Engineer, Propulsion Section, FAA, Seattle ACO Branch, 2200 South 216th St., Des Moines, WA 98198; phone and fax: 206-231-3556; email: *Rebel.Nichols@faa.gov*.

(j) Material Incorporated by Reference

None.

Issued in Des Moines, Washington, on January 23, 2019.

Jeffrey E. Duven,

Director, System Oversight Division, Aircraft Certification Service.

[FR Doc. 2019-00297 Filed 1-28-19; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[Docket No. DEA-421]

Schedules of Controlled Substances: Placement of MAB-CHMINACA in Schedule I

AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final rule.

SUMMARY: The Drug Enforcement Administration places *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action continues the imposition of the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on

persons who handle (manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle MAB-CHMINACA.

DATES: Effective January 29, 2019.

FOR FURTHER INFORMATION CONTACT: Regulatory Drafting and Policy Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152; Telephone: (202) 598-8953.

SUPPLEMENTARY INFORMATION:

Legal Authority

Under the Controlled Substances Act (CSA), each controlled substance is classified into one of five schedules based upon its potential for abuse, its currently accepted medical use, and the degree of dependence the substance may cause. 21 U.S.C. 812. The initial schedules of controlled substances established by Congress are found at 21 U.S.C. 812(c), and the current list of scheduled substances is published at 21 CFR part 1308.

Pursuant to 21 U.S.C. 811(a)(1), the Attorney General may, by rule, “add to such a schedule or transfer between such schedules any drug or other substance if he (A) finds that such drug or other substance has a potential for abuse, and (B) makes with respect to such drug or other substance the findings prescribed by subsection (b) of section 812 of this title for the schedule in which such drug is to be placed. . . .” The Attorney General has delegated scheduling authority under 21 U.S.C. 811 to the Administrator of the DEA (Administrator). 28 CFR 0.100.

The CSA provides that proceedings for the issuance, amendment, or repeal of the scheduling of any drug or other substance may be initiated by the Attorney General (1) on his own motion; (2) at the request of the Secretary of the Department of Health and Human Services (HHS);¹ or (3) on the petition of any interested party. 21 U.S.C. 811(a). This action was initiated on the Attorney General’s own motion, as delegated to the Administrator, and is supported by, *inter alia*, a

recommendation from the Acting Assistant Secretary for Health of the HHS (Acting Assistant Secretary) and an evaluation of all relevant data by the DEA. This action continues the imposition of the regulatory controls and administrative, civil, and criminal sanctions of schedule I controlled substances on any person who handles or proposes to handle MAB-CHMINACA.

Background

On February 5, 2016, the DEA published a final order in the **Federal Register** amending 21 CFR 1308.11(h) to temporarily place the synthetic cannabinoid *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (other names: MAB-CHMINACA; ADB-CHMINACA) in schedule I of the CSA pursuant to the temporary scheduling provisions of 21 U.S.C. 811(h). 81 FR 6171. That final order was effective on the date of publication, and was based on findings by the Acting Administrator of the DEA (Acting Administrator) that the temporary scheduling of this synthetic cannabinoid was necessary to avoid an imminent hazard to the public safety pursuant to 21 U.S.C. 811(h)(1). Section 201(h)(2) of the CSA, 21 U.S.C. 811(h)(2), requires that the temporary control of this substance expire two years from the issuance date of the scheduling order, on or before February 4, 2018. However, the CSA also provides that during the pendency of proceedings under 21 U.S.C. 811(a)(1), with respect to the substance, the temporary scheduling of that substance could be extended for up to one year. Accordingly, on January 30, 2018, the DEA extended the temporary scheduling of MAB-CHMINACA by one year, or until February 5, 2019. 83 FR 4411. Also, on January 30, 2018, the DEA published a notice of proposed rulemaking (NPRM) to permanently control MAB-CHMINACA in schedule I of the CSA. 83 FR 4406. Specifically, the DEA proposed to add this synthetic cannabinoid to the hallucinogenic substances list under 21 CFR 1308.11(d).

DEA and HHS Eight Factor Analyses

On January 19, 2018, the HHS provided the DEA with a scientific and medical evaluation document prepared by the Food and Drug Administration (FDA) entitled “Basis for the Recommendation to Place *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA), and its salts, in Schedule I of the Controlled Substances Act.”

After considering the eight factors in 21 U.S.C. 811(c), each substance’s abuse potential, lack of legitimate medical use in the United States, and lack of accepted safety for use under medical supervision pursuant to 21 U.S.C. 812(b), the Acting Assistant Secretary recommended that MAB-CHMINACA be controlled in schedule I of the CSA. In response, the DEA conducted its own eightfactor analysis of MAB-CHMINACA. The DEA and HHS analyses are available in their entirety in the public docket for this rule (Docket Number DEA-421/DEA-2018-0001) at <http://www.regulations.gov> under “Supporting Documents.”

Determination to Schedule MAB-CHMINACA

After a review of the available data, including the scientific and medical evaluation, and the scheduling recommendations from the HHS, the DEA published an NPRM entitled “Schedules of Controlled Substances: Placement of MAB-CHMINACA into Schedule I.” This NPRM proposed to control MAB-CHMINACA, and its salts, isomers, and salts of isomers in schedule I of the CSA. 83 FR 4406, January 30, 2018. The proposed rule provided an opportunity for interested persons to file a request for hearing in accordance with the DEA regulations on or before March 1, 2018. No requests for such a hearing were received by the DEA. The NPRM also provided an opportunity for interested persons to submit written comments on the proposed rule on or before March 1, 2018.

Comments Received

The DEA received six comments on the proposed rule to control MAB-CHMINACA in schedule I of the CSA.

Not related to rulemaking: Four commenters submitted responses that did not pertain to the rulemaking and were not considered.

DEA’s Future Diversion Efforts: One commenter quoted various statements from the proposed rule pertaining to the risk of MAB-CHMINACA to the public health (*i.e.*, information about clusters of overdoses, deaths, and adverse health effects associated with these incidents) and questioned the DEA’s future response to stay ahead of synthetic cannabinoid manufacturers who alter the chemical formulation of substances to circumvent current controls.

DEA Response: The DEA continues to monitor various synthetic cannabinoids and has taken additional control actions against new substances as they are encountered. The DEA is continuing to use all available resources to address the

¹ As set forth in a memorandum of understanding entered into by the Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA), the FDA acts as the lead agency within the Department of Health and Human Services (HHS) in carrying out the Secretary’s scheduling responsibilities under the CSA, with the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. The Secretary of the HHS has delegated to the Assistant Secretary for Health of the HHS the authority to make domestic drug scheduling recommendations. 58 FR 35460, July 1, 1993.

issue of trafficking and abuse of novel psychoactive substances to safeguard the public from hazards associated with these substances.

Dissent for rulemaking: One commenter acknowledged that MAB-CHMINACA has no currently accepted medical use in treatment and there is a lack of accepted safety for its use under medical supervision. However, the commenter believes this does not represent the danger or high abuse potential of the substance, attributed to it by DEA. Rather, the commenter believes MAB-CHMINACA is so similar to tetrahydrocannabinol (THC) that its use is “a symptom of” the schedule I controls placed on THC, and questions the reliability of the data that DEA provided—as reported by state public health entities over a two-month period in 2015—to support Factor 4 (Its History and Current Pattern of Abuse). The commenter predicted that use of this drug has likely dropped since 2015 due to “medicinal THC use” becoming more acceptable by the general public nationwide, and therefore does not reflect the current abuse potential. Additionally, this commenter expressed concern that placing MAB-CHMINACA in schedule I would prevent medical research.

DEA Response: The DEA does not agree. Both the DEA and HHS analyses documented serious adverse effects including the deaths of individuals following the ingestion of MAB-CHMINACA. Pharmacology studies, overdose reports, law enforcement seizures, and other data collectively demonstrated the hazard to public safety and the dangers associated with this substance. With regard to the commenter’s prediction that abuse of MAB-CHMINACA will become secondary due to the notion that THC is becoming more widely accepted, it is important to note that the extent of trafficking and abuse of a given substance at a given time is not typically determined by a sole factor. Complex factors related to the substance’s abuse potential, market dynamics such as availability of similar other novel substances, and drug use trends in the drug abuser community are also considered when scheduling a substance. In fact, following temporary control of MAB-CHMINACA, several pharmacologically similar new substances appeared on the illicit market and the DEA has taken control actions on these substances. While MAB-CHMINACA continues to be abused in the United States, law enforcement encounters have decreased, as normally occur following the control of synthetic cannabinoids, including

MAB-CHMINACA. As with other dangerous substances, the placement of a drug in schedule I does require additional regulatory controls. The Diversion Control Division’s mission is to prevent, detect and investigate the diversion of controlled substances while ensuring an adequate and uninterrupted supply of these substances to meet legitimate medical, commercial and scientific needs. The DEA ensures that adequate security measures and background investigations are conducted for researchers who have legitimate need to conduct research and development with schedule I controlled synthetic drug substances.

Scheduling Conclusion

After consideration of the relevant matter presented as a result of public comments, the scientific and medical evaluations and accompanying recommendation of HHS, and after its own eight-factor evaluation, the DEA finds that these facts and all other relevant data constitute substantial evidence of potential for abuse of MAB-CHMINACA. As such, the DEA is permanently scheduling MAB-CHMINACA as a controlled substance under the CSA.

Determination of Appropriate Schedule

The CSA establishes five schedules of controlled substances known as schedules I, II, III, IV, and V. The CSA also outlines the findings required to place a drug or other substance in any particular schedule. 21 U.S.C. 812(b). After consideration of the analyses and recommendations of the Assistant Secretary and review of all other available data, the Acting Administrator, pursuant to 21 U.S.C. 811(a) and 812(b)(1), finds that:

(1) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA) has a high potential for abuse that is comparable to other schedule I substances such as delta-9-tetrahydrocannabinol (Δ^9 -THC) and JWH-018;

(2) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA) has no currently accepted medical use in treatment in the United States; and

(3) There is a lack of accepted safety for use of *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA) under medical supervision.

Based on these findings, the Acting Administrator concludes that *N*-(1-

amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA), including its salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible, warrants control in schedule I of the CSA. 21 U.S.C. 812(b)(1).

Requirements for Handling MAB-CHMINACA

MAB-CHMINACA will continue² to be subject to the CSA’s schedule I regulatory controls and administrative, civil, and criminal sanctions applicable to the manufacture, distribution, dispensing, importing, exporting, research, and conduct of instructional activities, including the following:

1. **Registration.** Any person who handles (manufactures, distributes, imports, exports, engages in research, or conducts instructional activities or chemical analysis with, or possesses), or who desires to handle, MAB-CHMINACA must be registered with the DEA to conduct such activities pursuant to 21 U.S.C. 822, 823, 957, and 958 and in accordance with 21 CFR parts 1301 and 1312.

2. **Security.** MAB-CHMINACA is subject to schedule I security requirements and must be handled and stored pursuant to 21 U.S.C. 821, 823, 871(b) and in accordance with 21 CFR 1301.71–1301.93.

3. **Labeling and Packaging.** All labels and labeling for commercial containers of MAB-CHMINACA must be in compliance with 21 U.S.C. 825 and 958(e), and be in accordance with 21 CFR part 1302.

4. **Quota.** Only registered manufacturers are permitted to manufacture MAB-CHMINACA in accordance with a quota assigned pursuant to 21 U.S.C. 826 and in accordance with 21 CFR part 1303.

5. **Inventory.** Every DEA registrant who possesses any quantity of MAB-CHMINACA on the effective date of this final rule, must take an inventory of all stocks of these substances on hand as of January 29, 2019, pursuant to 21 U.S.C. 827 and 958 and in accordance with 21 CFR 1304.03, 1304.04, and 1304.11 (a) and (d). Current DEA registrants shall have 30 calendar days from the effective date of this order to be in compliance with all inventory requirements.

After the initial inventory, every DEA registrant must take a new inventory of all controlled substances (including MAB-CHMINACA) on hand on a

² MAB-CHMINACA is currently subject to schedule I controls on a temporary basis, pursuant to 21 U.S.C. 811(h). 81 FR 6171, Feb. 5, 2016.

biennial basis, pursuant to 21 U.S.C. 827 and 958, and in accordance with 21 CFR 1304.03, 1304.04, and 1304.11.

6. *Records and Reports.* Every DEA registrant must maintain records and submit reports with respect to MAB-CHMINACA pursuant to 21 U.S.C. 827 and 958(e), and in accordance with 21 CFR parts 1304 and 1312.

7. *Order Forms.* Every DEA registrant who distributes MAB-CHMINACA must continue to comply with the order form requirements, pursuant to 21 U.S.C. 828, and 21 CFR part 1305.

8. *Importation and Exportation.* All importation and exportation of MAB-CHMINACA must continue to be in compliance with 21 U.S.C. 952, 953, 957, and 958, and in accordance with 21 CFR part 1312.

9. *Liability.* Any activity involving MAB-CHMINACA not authorized by, or in violation of, the CSA or its implementing regulations is unlawful, and may subject the person to administrative, civil, and/or criminal sanctions.

Regulatory Analyses

Executive Orders 12866, 13563, and 13771, Regulatory Planning and Review, Improving Regulation and Regulatory Review, and Reducing Regulation and Controlling Regulatory Costs

In accordance with 21 U.S.C. 811(a), this scheduling action is subject to formal rulemaking procedures done “on the record after opportunity for a hearing,” which are conducted pursuant to the provisions of 5 U.S.C. 556 and 557. The CSA sets forth the criteria for scheduling a drug or other substance. Such actions are exempt from review by the Office of Management and Budget (OMB) pursuant to section 3(d)(1) of Executive Order 12866 and the principles reaffirmed in Executive Order 13563.

This final rule does not meet the definition of an Executive Order 13771 regulatory action. OMB has previously determined that formal rulemaking actions concerning the scheduling of controlled substances, such as this rule, are not significant regulatory actions under Section 3(f) of Executive Order 12866.

Executive Order 12988

This regulation meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 to eliminate drafting errors and ambiguity, minimize litigation, provide a clear legal standard for affected conduct, and promote simplification and burden reduction.

Executive Order 13132

This rulemaking does not have federalism implications warranting the application of Executive Order 13132. The rule does not have substantial direct effects on the States, on the relationship between the national government and the States, or the distribution of power and responsibilities among the various levels of government.

Executive Order 13175

This rule does not have tribal implications warranting the application of Executive Order 13175. It does not have substantial direct effects on one or more Indian tribes, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes.

Regulatory Flexibility Act

The Acting Administrator, in accordance with the Regulatory Flexibility Act, 5 U.S.C. 601–602, has reviewed this final rule and by approving it certifies that it will not have a significant economic impact on a substantial number of small entities. On February 6, 2016, the DEA published a final order to temporarily place this substance in schedule I of the CSA pursuant to the temporary scheduling provisions of 21 U.S.C. 811(h). The DEA estimates that all entities handling or planning to handle these substances have already established and implemented the systems and processes required to handle MAB-CHMINACA. As of January 2018, there were 16 registrations authorized to handle MAB-CHMINACA specifically, as well as a number of registered analytical labs that are authorized to handle schedule I controlled substances generally. These 16 registrations represent 14 entities, of which 8 are small entities. Therefore, the DEA estimates eight small entities are affected by this rule.

A review of the 16 registrations indicates that all entities that currently handle MAB-CHMINACA also handle other schedule I controlled substances, and have established and implemented (or maintain) the systems and processes required to handle MAB-CHMINACA. Therefore, the DEA anticipates that this rule will impose minimal or no economic impact on any affected entities; and thus, will not have a significant economic impact on any of the eight affected small entities. Therefore, the DEA has concluded that this rule will not have a significant effect on a substantial number of small entities.

Unfunded Mandates Reform Act of 1995

In accordance with the Unfunded Mandates Reform Act (UMRA) of 1995, 2 U.S.C. 1501 *et seq.*, the DEA has determined and certifies that this action would not result in any Federal mandate that may result “in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of \$100,000,000 or more (adjusted for inflation) in any one year * * *.” Therefore, neither a Small Government Agency Plan nor any other action is required under UMRA of 1995.

Paperwork Reduction Act of 1995

This action does not impose a new collection of information under the Paperwork Reduction Act of 1995. 44 U.S.C. 3501–3521. This action would not impose recordkeeping or reporting requirements on State or local governments, individuals, businesses, or organizations. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Congressional Review Act

This rule is not a major rule as defined by the Congressional Review Act (CRA), 5 U.S.C. 804. This rule will not result in: “an annual effect on the economy of \$100,000,000 or more; a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based enterprises to compete with foreign-based enterprises in domestic and export markets.” However, pursuant to the CRA, the DEA has submitted a copy of this final rule to both Houses of Congress and to the Comptroller General.

List of Subjects in 21 CFR Part 1308

Administrative practice and procedure, Drug traffic control, Reporting and recordkeeping requirements.

For the reasons set out above, 21 CFR part 1308 is amended as follows:

PART 1308—SCHEDULES OF CONTROLLED SUBSTANCES

■ 1. The authority citation for 21 CFR part 1308 continues to read as follows:

Authority: 21 U.S.C. 811, 812, 871(b), 956(b) unless otherwise noted.

■ 2. In § 1308.11, add paragraph (d)(72) and remove and reserve paragraph (h)(1).

The addition to read as follows:

§ 1308.11 Schedule I.

* * * * *

(d) * * *
(72) *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA).....(7032)

* * * * *

Dated: January 18, 2019.

Uttam Dhillon,
Acting Administrator.

[FR Doc. 2019-00254 Filed 1-28-19; 8:45 am]

BILLING CODE 4410-09-P

Proposed Rules

Federal Register

Vol. 84, No. 19

Tuesday, January 29, 2019

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF ENERGY

10 CFR Parts 430 and 431

[EERE-2018-BT-STD-0018]

Energy Conservation Program: Energy Conservation Standards for Residential Furnaces and Commercial Water Heaters

AGENCY: Office of Energy Efficiency and Renewable Energy, Department of Energy.

ACTION: Notice of petition for rulemaking; extension of public comment period.

SUMMARY: On November 1, 2018, the U.S. Department of Energy (“DOE”) published in the **Federal Register** a notice of petition for rulemaking and request for comment regarding whether DOE should issue an interpretive rule stating that DOE’s proposed energy conservation standards for residential furnaces and commercial water heaters would result in the unavailability of “performance characteristics” within the meaning of the Energy Policy and Conservation Act of 1975, as amended, and withdraw its proposals for amended standards for those products/equipment based upon such findings. The comment period in that notice was set to close on January 30, 2019. In the intervening period, DOE received two requests from interested parties seeking an extension of the comment period in order to develop additional data relevant to the petition. This notice announces an extension of the public comment period for submitting comments in response to that notice of petition for rulemaking. The comment period is hereby extended by 30 days to March 1, 2019.

DATES: The comment period for the notice of petition for rulemaking and request for comment published on November 1, 2018 (83 FR 54883) is extended. Written comments and information are requested and will be accepted on or before March 1, 2019.

ADDRESSES: Interested persons are encouraged to submit comments,

identified by “Energy Conservation Standards for Residential Furnaces and Commercial Water Heaters” and Docket No. EERE-2018-BT-STD-0018, by any of the following methods:

1. *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.

2. *Email:* ResFurnaceCommWaterHeater2018STD0018@ee.doe.gov. Include Docket No. EERE-2018-BT-STD-0018 in the subject line of the message.

3. *Postal Mail:* Appliance and Equipment Standards Program, U.S. Department of Energy, Building Technologies Office, Mailstop EE-5B, 1000 Independence Avenue SW, Washington, DC, 20585-0121. If possible, please submit all items on a compact disc (“CD”), in which case it is not necessary to include printed copies.

4. *Hand Delivery/Courier:* Appliance and Equipment Standards Program, U.S. Department of Energy, Building Technologies Office, 950 L’Enfant Plaza SW, 6th Floor, Washington, DC, 20024. Telephone: (202) 287-1445. If possible, please submit all items on a CD, in which case it is not necessary to include printed copies.

No telefacsimilies (faxes) will be accepted.

Docket: The docket for this activity, which includes **Federal Register** notices, comments, and other supporting documents/materials, is available for review at <http://www.regulations.gov>. All documents in the docket are listed in the <http://www.regulations.gov> index. However, some documents listed in the index, such as those containing information that is exempt from public disclosure, may not be publicly available. The docket web page can be found at <https://www.regulations.gov/docket?D=EERE-2018-BT-STD-0018>. The docket web page contains instructions on how to access all documents, including public comments, in the docket.

FOR FURTHER INFORMATION CONTACT: Mr. Eric Stas, U.S. Department of Energy, Office of the General Counsel, GC-33, 1000 Independence Avenue SW, Washington, DC 20585-0121. Telephone: (202) 586-5827. Email: Eric.Stas@hq.doe.gov.

SUPPLEMENTARY INFORMATION: On November 1, 2018, the U.S. Department of Energy (“DOE”) published in the **Federal Register** a notice of petition for

rulemaking and request for comment regarding whether DOE should issue an interpretive rule stating that DOE’s proposed energy conservation standards for residential furnaces and commercial water heaters would result in the unavailability of “performance characteristics” within the meaning of the Energy Policy and Conservation Act of 1975 (EPCA), as amended (42 U.S.C. 6291 *et seq.*) and withdraw its proposals for amended standards for such products/equipment based upon such findings (the “notice of petition”). 83 FR 54883. (The notice of petition can be found at <https://www.regulations.gov/document?D=EERE-2018-BT-STD-0018-0002>.) The document provided for submitting written comments and information by January 30, 2019. In the intervening period, DOE has received a request from the Natural Resources Defense Council; Earthjustice; Appliance Standards Awareness Project; American Council for an Energy-Efficient Economy; Consumer Federation of America; Alliance to Save Energy; National Consumer Law Center; and Northeast Energy Efficiency Partnerships (jointly the “Joint Commenters”) dated January 18, 2019, to provide an additional 30 days to submit comments pertaining to the notice of petition. DOE also received a separate request from the Northwest Energy Efficiency Alliance (NEEA) dated January 18, 2019, which similarly requested a 30-day comment period extension until March 1, 2019. These requests can be found at <https://www.regulations.gov/document?D=EERE-2018-BT-STD-0018-0008> and <https://www.regulations.gov/document?D=EERE-2018-BT-STD-0018-0009>, respectively. Both requests stated that additional time is needed to develop data and information relevant to consideration of the petition, and NEEA specifically referenced a market research study they had commissioned which is nearing completion.

An extension of the comment period would allow additional time for the Joint Commenters, NEEA, and other interested parties to consider the issues presented in the notice of petition, gather any additional data and information, and submit comments to DOE.

In light of the requests from the Joint Commenters and NEEA, DOE has determined that a 30-day extension of

the public comment period is appropriate. Accordingly, the comment period is extended to March 1, 2019.

Signed in Washington, DC, on January 23, 2019.

Daniel R Simmons,
Assistant Secretary, Energy Efficiency and Renewable Energy.

[FR Doc. 2019-00257 Filed 1-28-19; 8:45 am]

BILLING CODE 6450-01-P

Notices

Federal Register

Vol. 84, No. 19

Tuesday, January 29, 2019

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF EDUCATION

Eligibility Designations and Applications for Waiving Eligibility Requirements; Programs Under Parts A and F of Title III and Programs Under Title V of the Higher Education Act of 1965, as Amended (HEA)

AGENCY: Office of Postsecondary Education, Department of Education (Department).

ACTION: Notice.

SUMMARY: The Department announces the process for designation of eligible institutions and invites applications for waivers of eligibility requirements for fiscal year (FY) 2019, for the programs under parts A and F of title III and programs under title V of the HEA specified in this notice.

DATES:

Applications Available: January 29, 2019.

Deadline for Transmittal of Applications: February 28, 2019.

FOR FURTHER INFORMATION CONTACT:

Christopher Smith, Institutional Service, U.S. Department of Education, 400 Maryland Avenue SW, Room 250–10, Washington, DC 20202. Telephone: (202)453–7946. Email: Christopher.smith@ed.gov.

Jason Cottrell, Institutional Service, U.S. Department of Education, 400 Maryland Avenue SW, Room 250–50, Washington, DC 20202. Telephone: (202)453–7530. Email: Jason.Cottrell@ed.gov.

If you use a telecommunications device for the deaf or a text telephone, call the Federal Relay Service, toll free, at 1–800–877–8339.

Section 312 of the HEA and 34 CFR 607.2–607.5 include most of the basic eligibility requirements for grant programs authorized under titles III and V of the HEA. Section 312(b)(1)(B) of the HEA provides that, to be eligible for these programs, an institution of higher

education's average "educational and general expenditures" (E&G) per full-time equivalent (FTE) undergraduate student must be less than the average E&G expenditures per FTE undergraduate student of institutions that offer similar instruction in that year.

The National Center for Education Statistics (NCES) calculates Core Expenses per FTE of institutions, a statistic similar to E&G per FTE. Both E&G per FTE and Core Expenses per FTE are based on regular operational expenditures of institutions (excluding auxiliary enterprises, independent operations, and hospital expenses). They differ only in that E&G per FTE is based on fall undergraduate enrollment, while Core Expenses per FTE is based on 12-month undergraduate enrollment for the academic year.

To avoid inconsistency in the data submitted to, and produced by, the Department, for the purpose of section 312(b)(1)(B) of the HEA, E&G per FTE is calculated using the same methodology as Core Expenses per FTE. Accordingly, the Department will apply the NCES methodology for calculating Core Expenses per FTE. Institutions requesting an eligibility exemption determination must use the Core Expenses per FTE data reported to NCES' Integrated Postsecondary Education Data System (IPEDS) for the most currently available academic year, in this case academic year 2016–2017.

SUPPLEMENTARY INFORMATION:

Full Text of Announcement

I. Funding Opportunity Description

Background and Purpose of Programs: The Department announces the process for designation of eligible institutions and invites applications for waivers of eligibility requirements for FY 2019, for the following programs:

1. *Programs authorized under title III, part A of the HEA:* Strengthening Institutions Program (Part A SIP), Alaska Native and Native Hawaiian-Serving Institutions (Part A ANNH), Predominantly Black Institutions (Part A PBI), Native American-Serving Nontribal Institutions (Part A NASNTI), and Asian American and Native American Pacific Islander-Serving Institutions (Part A AANAPISI).

2. *Programs authorized under title III, part F of the HEA:* Hispanic-Serving Institutions STEM and Articulation

(Part F, HSI STEM and Articulation), Predominantly Black Institutions (Part F PBI), Alaska Native and Native Hawaiian-Serving Institutions (Part F ANNH), Native American-Serving Nontribal Institutions (Part F NASNTI), and Asian American and Native American Pacific Islander-Serving Institutions (Part F AANAPISI).

3. *Programs authorized under title V of the HEA:* Developing Hispanic-Serving Institutions (HSI) and Promoting Postbaccalaureate Opportunities for Hispanic Americans (PPOHA).

The Part A SIP, Part A ANNH, Part A PBI, Part A NASNTI, and Part A AANAPISI programs are authorized under title III, part A, of the HEA. The HSI and PPOHA programs are authorized under title V of the HEA. The Part F, HSI STEM and Articulation, Part F PBI, Part F AANAPISI, Part F ANNH, and Part F NASNTI programs are authorized under title III, part F of the HEA. Please note that certain programs in this notice have the same or similar names as other programs that are authorized under a different statutory authority. For this reason, we specify the statutory authority as part of the acronym for certain programs.

Under the programs discussed above, institutions are eligible to apply for grants if they meet specific statutory and regulatory eligibility requirements. An institution of higher education (IHE) that is designated as an eligible institution may also receive a waiver of certain non-Federal cost-sharing requirements for one year under the Federal Supplemental Educational Opportunity Grant (FSEOG) program authorized by title IV, part A of the HEA and the Federal Work-Study (FWS) program authorized by section 443 of the HEA. Qualified (eligible) institutions may receive the FSEOG and FWS waivers for one year even if they do not receive a grant under a title III or V grant program. An applicant that receives a grant from the Student Support Services (SSS) program that is authorized under section 402D of the HEA, 20 U.S.C. 1070a–14, may receive a waiver of the required non-Federal cost share for institutions for the duration of the grant. An applicant that receives a grant from the Undergraduate International Studies and Foreign Language (UISFL) program that is authorized under section 604 of the HEA, 20 U.S.C. 1124, may receive a

waiver or reduction of the required non-Federal cost share for institutions for the duration of the grant.

Special Note: To qualify as an eligible institution under the grant programs listed in this notice, your institution must satisfy several criteria. For most of these programs, these criteria include those that relate to the enrollment of needy students and to the Core Expenses per FTE student count for a specified base year. The most recent data available in IPEDS for Core Expenses per FTE are for base year 2016–2017. In order to award FY 2019 grants in a timely manner, we will use these data to evaluate eligibility.

Accordingly, each institution interested in either applying for a new grant under the title III or V programs addressed in this notice, or requesting a waiver of the non-Federal cost share, must be designated as an eligible institution for FY 2019. Under the HEA, any IHE interested in applying for a grant under any of these programs must first be designated as an eligible institution. (34 CFR 606.5 and 607.5).

Eligible Applicants: The eligibility requirements for the programs authorized under part A of title III of the HEA are in sections 312 and 317–320 of the HEA (20 U.S.C. 1058, 1059d–1059g) and in 34 CFR 607.2 through 607.5. The regulations may be accessed at www.ecfr.gov/cgi-bin/text-idx?SID=bc12bf5d685021e069cd1a15352b381a&mc=true&node=pt34.3.607&rgn=div5. The eligibility requirements for the programs authorized by part F of title III of the HEA are in section 371 of the HEA (20 U.S.C. 1067q). There are currently no specific regulations for these programs.

The eligibility requirements for the title V HSI program are in part A of title V of the HEA and in 34 CFR 606.2 through 34 CFR 606.5. The regulations may be accessed at www.ecfr.gov/cgi-bin/text-idx?SID=bc12bf5d685021e069cd1a15352b381a&mc=true&node=pt34.3.606&rgn=div5.

The requirements for the PPOHA program are in part B of title V of the HEA and in the notice of final requirements published in the **Federal Register** on July 27, 2010 (75 FR 44055), and in 34 CFR 606.2(a) and (b), and 606.3 through 606.5.

The Department has instituted a process known as the Eligibility Matrix (EM), under which we will use information submitted by IHEs to IPEDS to determine which institutions meet the basic eligibility requirements for the programs authorized by titles III or V of the HEA listed above. We will use enrollment and fiscal data for the 2016–2017 year submitted by institutions to IPEDS to make eligibility determinations for FY 2019. Beginning

January 7, 2019, an institution will be able to review the Department's decision on whether it is eligible for the grant programs authorized by titles III or V of the HEA through this process by checking the institution's eligibility in the eligibility system linked through the Department's Institutional Service Eligibility website: <http://www2.ed.gov/about/offices/list/ope/ides/eligibility.html>.

Please note that through this process, the Department does not certify, nor designate, an institution as a Historically Black College or University, Tribally Controlled College or University, Minority-Serving Institution, or Hispanic-Serving Institution. The Department's determination that an institution is eligible is solely for the purpose of the institution's ability to apply for and receive grants under certain programs as discussed in this notice.

The EM is part of the Department's eligibility data system. The EM is a read-only worksheet that lists all potentially eligible postsecondary institutions, as determined by the Department using the data described above. If the entry for your institution in the EM shows that your institution is eligible to apply for a grant for a particular program, and you plan to submit an application for a grant in that program, you will not need to apply for eligibility or for a waiver through the process described in this notice. Rather, you may print out the eligibility letter directly. However, if the EM does not show that your institution is eligible for a program in which you plan to apply for a grant, you must submit an application as discussed in this notice before the February 8, 2019 deadline.

To check your institution's eligibility in the EM, go to the website <https://hepis.ed.gov/title3and5/>, click the "Application for Designation as an Eligible Institution" link, and then click the "Check Eligibility" link. You may search the EM by institution name, IPEDS unit ID number, or OPE ID number. If you are inquiring about general eligibility, look up your institution's name under the SIP column. If you are inquiring about specific program eligibility, look under that program's column.

If the EM does not show that your institution is eligible for a program, or if your institution does not appear in the eligibility system, or if you disagree with the eligibility determination reflected in the eligibility system, you can apply for a waiver or reconsideration through the process described in this notice. The application process is the same as in previous years;

you will choose the waiver option on the website at <https://hepis.ed.gov/title3and5/> and submit your institution's application.

Enrollment of needy students: For title III and V programs (excluding the PBI programs), an institution is considered to have an enrollment of needy students if: (1) At least 50 percent of its degree-seeking students received financial assistance under the Federal Pell Grant, FSEOG, FWS, or the Federal Perkins Loan programs; or (2) the percentage of its undergraduate degree-seeking students who were enrolled on at least a half-time basis and received Federal Pell Grants exceeded the average percentage of undergraduate degree students who were enrolled on at least a half-time basis and received Federal Pell Grants at comparable institutions that offer similar instruction.

To qualify under criterion 2, an institution's Federal Pell Grant percentage for base year 2016–2017 must be more than the average for its category of comparable institutions provided in the 2016–2017 Average Pell Grant and Core Expenses per FTE Student table in this notice. If your institution qualifies under the first criterion, under which at least 50 percent of its degree-seeking students received financial assistance under one of several Federal student aid programs (the Federal Pell Grant, FSEOG, FWS, or the Federal Perkins Loan programs), but not the second criterion, under which an institution's Federal Pell Grant percentage for base year 2016–2017 must be more than the average for its category of comparable institutions provided in the 2016–2017 Average Pell Grant and Core Expenses per FTE student table in this notice, you must submit an application including the requested data, which is not available in IPEDS.

For the definition of "Enrollment of Needy Students," for purposes of the Part A PBI program, see section 318(b)(2) of the HEA, and for purposes of the Part F PBI program, see section 371(c)(9) of the HEA.

Core expenses per FTE student: For the Title III, Part A SIP; Part A ANNH; Part A PBI; Part A NASNTI; Part A AANAPISI; Title III, Part F HSI STEM and Articulation; Part F PBI; Part F AANAPISI; Part F ANNH; Part F NASNTI; Title V, Part A HSI; and Title V, Part B PPOHA programs, an institution should compare its base year 2016–2017 Core Expenses per FTE student to the average Core Expenses per FTE student for its category of comparable institutions in the base year 2016–2017 Average Pell Grant and

Average Core Expenses per FTE Student Table in this notice. The institution meets this eligibility requirement under these programs if its Core Expenses for the 2016–2017 base year are less than the average for its category of comparable institutions.

Core Expenses are defined as the total expenses for the essential education activities of the institution. Core Expenses for public institutions reporting under the Governmental Accounting Standards Board (GASB) requirements include expenses for

instruction, research, public service, academic support, student services, institutional support, operation and maintenance of plant, depreciation, scholarships and fellowships, interest, and other operating and non-operating expenses. Core Expenses for institutions reporting under the Financial Accounting Standards Board (FASB) standards (primarily private, not-for-profit, and for-profit) include expenses for instruction, research, public service, academic support, student services, institutional support, net grant aid to

students, and other expenses. Do not include Federal student financial aid. For both FASB and GASB institutions, core expenses exclude expenses for auxiliary enterprises (e.g., bookstores, dormitories), hospitals, and independent operations.

The following table identifies the relevant average Federal Pell Grant percentages for the base year 2016–2017 and the relevant Core Expenses per FTE student for the base year 2016–2017 for the four categories of comparable institutions:

Type of institution	Base year 2016–2017 average pell grant percentage	Base year 2016–2017 average core expenses per FTE student
Two-year Public Institutions	36	\$13,798
Two-year Non-profit Private Institutions	58	15,961
Four-year Public Institutions	37	30,911
Four-year Non-profit Private Institutions	39	39,567

Waiver Information: IHEs that do not meet the needy student enrollment requirement or the Core Expenses per FTE requirement may apply to the Secretary for a waiver of these requirements, as described in sections 392 and 522 of the HEA, and the implementing regulations at 34 CFR 606.3(b), 606.4(c) and (d), 607.3(b), and 607.4(c) and (d).

IHEs requesting a waiver of the needy student enrollment requirement or the Core Expenses per FTE requirement must include in their application detailed evidence supporting the waiver request, as described in the instructions for completing the application.

The regulations governing the Secretary’s authority to grant a waiver of the needy student requirement, 34 CFR 606.3(b)(2) and (3) and 607.3(b)(2) and

(3), refer to “low-income” students or families. The regulations at 34 CFR 606.3(c) and 607.3(c) define “low-income” as an amount that does not exceed 150 percent of the amount equal to the poverty level, as established by the U.S. Census Bureau.

For the purposes of this waiver provision, the following table sets forth the low-income levels (at 150%) for various sizes of families:

2017 ANNUAL LOW-INCOME LEVELS

Size of family unit	Family income for the 48 contiguous states, DC, and outlying jurisdictions	Family income for Alaska	Family income for Hawaii
1	\$18,090	\$22,590	\$20,790
2	24,360	30,435	28,005
3	30,630	38,280	35,220
4	36,900	46,125	42,435
5	43,170	53,970	49,650
6	49,440	61,815	56,865
7	55,710	69,660	64,080
8	61,980	77,505	71,295

Note: We use the 2017 annual low-income levels because those are the amounts that apply to the family income reported by students enrolled for the fall 2016 semester. For family units with more than eight members, add the following amount for each additional family member: \$6,270 for the contiguous 48 States, the District of Columbia, and outlying jurisdictions; \$7,845 for Alaska; and \$7,215 for Hawaii.

The figures shown under family income represent amounts equal to 150 percent of the family income levels

established by the U.S. Census Bureau for determining poverty status. The poverty guidelines were published on January 31, 2017, in the **Federal Register** by the U.S. Department of Health and Human Services (82 FR 8831).

Information about “metropolitan statistical areas” referenced in 34 CFR 606.3(b)(4) and 607.3(b)(4) may be obtained at: www.census.gov/prod/2010pubs/10smadb/appendixc.pdf.

www.census.gov/prod/2008pubs/07ccdb/appd.pdf.

Electronic Submission of Waiver Applications: If your institution does not appear in the eligibility system as one that is eligible for the program under which you plan to apply for a grant, you must submit an application for a waiver of the eligibility requirements. To request a waiver, you must upload a narrative at: <https://hepis.ed.gov/title3and5/>.

Exception to the Electronic Submission Requirement: You qualify for an exception to the electronic submission requirement, and may submit your application in paper format, if you are unable to submit an application electronically because—

- You do not have access to the internet; or
- You do not have the capacity to upload documents to the website;

and

- No later than two weeks before the application deadline date (14 calendar days or, if the fourteenth calendar day before the application deadline date falls on a Federal holiday, the next business day following the Federal holiday), you may mail or fax a written statement to the Department, explaining which of the two grounds for an exception prevents you from using the internet to submit your application. If you mail your written statement to the Department, it must be postmarked no later than two weeks before the application deadline date. If you fax your written statement to the Department, we must receive the faxed statement no later than two weeks before the application deadline date.

Mail or fax your statement to: Christopher Smith or Jason Cottrell, U.S. Department of Education, 400 Maryland Avenue SW, Room 250–10, Washington, DC 20202. Fax: (202) 401–8466.

Your paper application must be submitted in accordance with the mail or hand delivery instructions described in this notice.

Submission of Paper Applications by Mail.

If you qualify for an exception to the electronic submission requirement, you may mail (through the U.S. Postal Service or a commercial carrier) your application to the Department. You must mail the original and two copies of your application, on or before the application deadline date, to the Department at the following address: Christopher Smith, U.S. Department of Education, 400 Maryland Avenue SW, Room 250–10, Washington, DC 20202.

You must show proof of mailing consisting of one of the following:

- (1) A legibly dated U.S. Postal Service postmark.
- (2) A legible mail receipt with the date of mailing stamped by the U.S. Postal Service.
- (3) A dated shipping label, invoice, or receipt from a commercial carrier.
- (4) Any other proof of mailing acceptable to the Secretary of the U.S. Department of Education.

If you mail your application through the U.S. Postal Service, we do not

accept either of the following as proof of mailing:

- (1) A private metered postmark.
- (2) A mail receipt that is not dated by the U.S. Postal Service.

Note: The U.S. Postal Service does not uniformly provide a dated postmark. Before relying on this method, you should check with your local post office.

We will not consider eligibility applications postmarked after the application deadline date.

Submission of Paper Applications by Hand Delivery.

If you qualify for an exception to the electronic submission requirement, you (or a courier service) may deliver your paper application to the Department by hand. You must deliver the application, on or before the application deadline date, to the Department at the following address: Christopher Smith, U.S. Department of Education, 400 Maryland Avenue SW, Room 250–10, Washington, DC 20202.

We accept hand deliveries daily between 8:00 a.m. and 4:30 p.m., Washington, DC time, except Saturdays, Sundays, and Federal holidays.

Applicable Regulations: (a) The Education Department General Administrative Regulations (EDGAR) in 34 CFR parts 75, 77, 79, 82, 84, 86, 97, 98, and 99. (b) The Office of Management and Budget Guidelines to Agencies on Governmentwide Debarment and Suspension (Nonprocurement) in 2 CFR 180, as adopted and amended as regulations of the Department in 2 CFR part 3485. (c) The Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards in 2 CFR part 200, as adopted and amended as regulations of the Department in 2 CFR part 3474. (d) The regulations for certain title III programs in 34 CFR part 607, and for the HSI program in 34 CFR part 606. (e) The notice of final requirements for the PPOHA program, published in the **Federal Register** on July 27, 2010 (75 FR 44055).

Note: The regulations in 34 CFR part 79 apply to all applicants except federally recognized Indian Tribes.

Note: The regulations in 34 CFR part 86 apply to IHEs only.

Note: There are no program-specific regulations for the Part A AANAPISI, Part A NASNTI, and Part A PBI programs or any of the title III, part F programs. Also, there have been amendments to the HEA since the Department last issued regulations for the programs established under titles III and V of the statute. Accordingly, we encourage each potential applicant to read the applicable sections of the HEA in order to fully

understand the eligibility requirements for the program for which they are applying.

II. Other Information

Accessible Format: Individuals with disabilities can obtain this document and a copy of the application in an accessible format (e.g., braille, large print, audio tape, or compact disc) on request to the contact person listed under **FOR FURTHER INFORMATION CONTACT**.

Electronic Access to This Document: The official version of this document is the document published in the **Federal Register**. Free internet access to the official edition of the **Federal Register** and the Code of Federal Regulations is available at www.govinfo.gov. At this site you can view this document, as well as all other documents of this Department published in the **Federal Register**, in text or Portable Document Format (PDF). To use PDF you must have Adobe Acrobat Reader, which is available free at the site.

You may also access documents of the Department published in the **Federal Register** by using the article search feature at: www.federalregister.gov. Specifically, through the advanced search feature at this site, you can limit your search to documents published by the Department.

Dated: January 22, 2019.

Diane Auer Jones,

Principal Deputy Under Secretary Delegated to Perform the Duties of Under Secretary and Assistant Secretary, Office of Postsecondary Education.

[FR Doc. 2019–00251 Filed 1–28–19; 8:45 am]

BILLING CODE 4000–01–P

DEPARTMENT OF EDUCATION

[Docket No.: ED–2019–ICCD–0005]

Agency Information Collection Activities; Comment Request; Evaluation of Preschool Special Education Practices Efficacy Study

AGENCY: Institute of Education Sciences (IES), Department of Education (ED).

ACTION: Notice.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, ED is proposing a reinstatement of a previously approved information collection.

DATES: Interested persons are invited to submit comments on or before April 1, 2019.

ADDRESSES: To access and review all the documents related to the information collection listed in this notice, please use <http://www.regulations.gov> by

searching the Docket ID number ED–2019–ICCD–0005. Comments submitted in response to this notice should be submitted electronically through the Federal eRulemaking Portal at <http://www.regulations.gov> by selecting the Docket ID number or via postal mail, commercial delivery, or hand delivery. If the [regulations.gov](http://www.regulations.gov) site is not available to the public for any reason, ED will temporarily accept comments at ICDocketMgr@ed.gov. Please include the docket ID number and the title of the information collection request when requesting documents or submitting comments. *Please note that comments submitted by fax or email and those submitted after the comment period will not be accepted.* Written requests for information or comments submitted by postal mail or delivery should be addressed to the Director of the Information Collection Clearance Division, U.S. Department of Education, 550 12th Street SW, PCP, Room 9089, Washington, DC 20202–0023.

FOR FURTHER INFORMATION CONTACT: For specific questions related to collection activities, please contact Yumiko Sekino, 202–374–0936.

SUPPLEMENTARY INFORMATION: The Department of Education (ED), in accordance with the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3506(c)(2)(A)), provides the general public and Federal agencies with an opportunity to comment on proposed, revised, and continuing collections of information. This helps the Department assess the impact of its information collection requirements and minimize the public's reporting burden. It also helps the public understand the Department's information collection requirements and provide the requested data in the desired format. ED is soliciting comments on the proposed information collection request (ICR) that is described below. The Department of Education is especially interested in public comment addressing the following issues: (1) Is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on the respondents, including through the use of information technology. Please note that written comments received in response to this notice will be considered public records.

Title of Collection: Evaluation of Preschool Special Education Practices Efficacy Study.

OMB Control Number: 1850–0916.

Type of Review: A reinstatement of a previously approved information collection.

Respondents/Affected Public: State, Local, and Tribal Governments.

Total Estimated Number of Annual Responses: 1,739.

Total Estimated Number of Annual Burden Hours: 455.

Abstract: This package requests clearance for data collection activities to support an efficacy study of an instructional framework designed to address the needs of all preschool children in inclusive classrooms. The efficacy study is part of the Evaluation of Preschool Special Education Practices (EPSEP), which is assessing the feasibility of a large-scale effectiveness study of an intervention for preschool children in inclusive classrooms. The main objective of the efficacy study is to test whether the Instructionally Enhanced Pyramid Model (IEPM) can be implemented with fidelity in inclusive preschool classrooms. IEPM is comprised of three established individual interventions for children with disabilities integrated together into a single comprehensive intervention for use with all children in inclusive preschool classrooms. The secondary objective is to provide initial evidence about IEPM's impacts on classroom and child outcomes. This efficacy study provides an important test of whether strategies for delivering content in a manner that meets the needs of each child with a disability can be integrated with an existing framework of teaching practices for inclusive preschool classes, thus helping all children participate and make progress in the general preschool curriculum. These strategies, which are called targeted instructional supports, have been tested separately but have not been tested as part of this framework.

The efficacy study will include data collection to conduct both implementation and impact analyses. The implementation analysis will use observation data to describe the fidelity of training and implementation. It also will draw on coaching logs and coach interviews to describe program implementation. In addition, responses to a teacher survey and teacher focus groups will provide information on teachers' backgrounds, professional experiences, and perspectives on IEPM implementation. The impact analysis will use data from observations of classroom inclusion quality and engagement, a child observation, a direct child assessment, and teacher

reports on child outcomes. The implementation and impact analyses also will use district administrative records to offer additional contextual and background information on the preschool program, its teachers, and enrolled children. These various data collection activities will be carried out between summer 2019 and summer 2021 during the two years that schools in the intervention group will implement IEPM (2019–2020 and 2020–2021 school years).

Dated: January 23, 2019.

Stephanie Valentine,

Acting Director, Information Collection Clearance Program, Information Management Branch, Office of the Chief Information Officer.

[FR Doc. 2019–00255 Filed 1–28–19; 8:45 am]

BILLING CODE 4000–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day–19–0212]

Agency Forms Undergoing Paperwork Reduction Act Review

In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled *National Hospital Care Survey* to the Office of Management and Budget (OMB) for review and approval. CDC previously published a “Proposed Data Collection Submitted for Public Comment and Recommendations” notice on September 13, 2018 to obtain comments from the public and affected agencies. CDC received four comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments.

CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that:

(a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Enhance the quality, utility, and clarity of the information to be collected;

(d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and

(e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639-7570 or send an email to *omb@cdc.gov*. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW., Washington, DC 20503 or by fax to (202) 395-5806. Provide written comments within 30 days of notice publication.

Proposed Project

National Hospital Care Survey (OMB Control No. 0920-0212, Exp. 01/31/2019)—Revision—National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

Section 306 of the Public Health Service (PHS) Act (42 U.S.C. 242k), as amended, authorizes that the Secretary of Health and Human Services (DHHS), acting through NCHS, shall collect statistics on the extent and nature of illness and disability of the population of the United States. This three-year clearance request for NHCS includes the collection of all inpatient and ambulatory Uniform Bill-04 (UB-04) claims data or electronic health record (EHR) data as well as the collection of hospital-level information via a questionnaire from a sample of 598 hospitals.

The NHCS collects data on patient care in hospital-based settings to describe patterns of health care delivery and utilization in the United States.

NHCS hospital-based settings include inpatient, emergency department (ED), and outpatient department (OPD). The survey will provide hospital utilization statistics for the Nation. In addition, the NHCS will also be able to monitor national trends in substance use-related ED visits including opioid visits.

NHCS consists of a nationally representative sample of 598 hospitals. These hospitals are currently being recruited, and participating hospitals are submitting all of their inpatient and ambulatory care patient data in the form of electronic UB-04 administrative claims or EHR data. Currently, hospital-level data are collected through a questionnaire administered via a web portal.

This revision seeks approval to continue voluntary recruitment of hospitals in the sample for the NHCS; continue the collection of hospital-level data through an initial intake questionnaire and an Annual Hospital Interview for all sampled hospitals; continue the collection of electronic data on inpatient discharges as well as ED and OPD visits through the collection of EHR data, UB-04 claims, or a state file; continue collection of substance-involved ED visit data through the ED component; eliminate medical record abstraction of a sample of ED and OPD visits as part of the design of the survey; and postpone frame development for free standing ambulatory care facilities.

NHCS collects data items at the hospital, patient, inpatient discharge, and visit levels. Hospital-level data items include ownership, number of staffed beds, hospital service type, and EHR adoption. Patient-level data items are collected from electronic data and include basic demographic information, personal identifiers, name, address, social security number (if available), and medical record number (if available). Discharge-level data are collected through the UB-04 claims or EHR data and include admission and discharge dates, diagnoses, diagnostic

services, and surgical and non-surgical procedures. Visit-level data are collected through EHR data and include reason for visit, diagnosis, procedures, medications, substances involved, and patient disposition.

NHCS data have distinct advantages. Through the collection of personal identifiers, NHCS data can be linked to outside datasets such as the National Death Index (OMB No. 0920-0215, Exp. Date 12/31/2019) to calculate post-discharge mortality. Additionally, NHCS offers unique opportunities to study opioid-involved health outcomes, such as repeat hospital encounters for opioid use and opioid-related mortality rates.

NHCS users include, but are not limited to, CDC, Congressional Research Office, Office of the Assistant Secretary for Planning and Evaluation (ASPE), National Institutes of Health, U.S. Food and Drug Administration (FDA), American Health Information Management Association (AHIMA), Centers for Medicare & Medicaid Services (CMS), Substance Abuse and Mental Health Services Administration (SAMHSA), Bureau of the Census, Office of National Drug Control Policy, state and local governments, and nonprofit organizations. Other users of these data include universities, research organizations, many in the private sector, foundations, and a variety of users in the media.

Data collected through NHCS are essential for evaluating the health status of the population, for the planning of programs and policy to improve health care delivery systems of the Nation, for studying morbidity trends, and for research activities in the health field. Historically, data have been used extensively in the development and monitoring of goals for the Year 2000, 2010, and 2020 Healthy People Objectives. There is no cost to respondents other than their time to participate. The total annualized burden is 7,080 hours.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Hospital Director of Health Information Management (DHIM) or Director of Health Information Technology (DHIT).	Initial Hospital Intake Questionnaire	150	1	1
Hospital Chief Executive Officer (CEO)/Chief Financial Officer (CFO).	Recruitment Survey Presentation	150	1	1
Hospital DHIM or DHIT	Prepare and transmit UB-04 or State File for Inpatient and Ambulatory.	399	12	1
Hospital DHIM or DHIT	Prepare and transmit EHR for Inpatient and Ambulatory.	199	4	1

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Hospital CEO/CFO	Annual Hospital Interview	598	1	2

Jeffrey M. Zirger,

Acting Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2019-00214 Filed 1-28-19; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-19-1170; Docket No. CDC-2018-0113]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice with comment period.

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on the data collection project titled “Canine leptospirosis surveillance in Puerto Rico.” This surveillance project aims to characterize the epidemiology of canine leptospirosis, assess the applicability of canine *Leptospira* vaccines used in Puerto Rico, and determine potential rodent, livestock, and wildlife reservoirs for leptospirosis. Findings from the study will be used to develop recommendations for the prevention of leptospirosis in dogs, focus human surveillance efforts, and guide further investigations on leptospirosis in Puerto Rico.

DATES: CDC must receive written comments on or before April 1, 2019.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2018-0113 by any of the following methods:

- *Federal eRulemaking Portal: Regulations.gov.* Follow the instructions for submitting comments.

- *Mail:* Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-D74, Atlanta, Georgia 30329.

Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to *Regulations.gov*.

Please note: Submit all comments through the Federal eRulemaking portal (regulations.gov) or by U.S. mail to the address listed above.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: *omb@cdc.gov*.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help:

1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
2. Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

3. Enhance the quality, utility, and clarity of the information to be collected; and

4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submissions of responses.

5. Assess information collection costs.

Proposed Project

Canine Leptospirosis Surveillance in Puerto Rico (OMB Control No. 0920-1170 Exp. Date 03/31/2019)—Revision—National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The Centers for Disease Control and Prevention (CDC) Bacterial Special Pathogens Branch (BSPB) requests for approval of revisions to existing data collection tools used in active surveillance for canine leptospirosis in Puerto Rico. The methods for data collection have not changed.

Active surveillance allows for the collection of prospective data on acute cases to determine the incidence and distribution of leptospirosis in dogs, assess risk factors for infection, characterize circulating *Leptospira* serovars and species, assess applicability of vaccines currently in use based on serovar determination, and assess rodent, livestock, and wildlife reservoirs of leptospirosis based on infecting serovars found in dogs. Findings from this study will aid in the development of evidence-based, targeted interventions for the prevention of canine leptospirosis, be used to focus human leptospirosis surveillance efforts, and guide future investigations on leptospirosis in humans and animals in Puerto Rico.

The information collection for which approval sought is in accordance with BSPB’s mission to prevent illness, disability, or death caused by bacterial zoonotic diseases through surveillance, epidemic investigations, epidemiologic and laboratory research, training and

public education. Authorizing Legislation comes from Section 301 of the Public Health Service Act (42 U.S.C. 241). Successful execution of BSPB's public health mission requires data collection activities in collaboration with the state health department in Puerto Rico and with local veterinary clinics and animal shelters participating in the study.

These activities include collecting information about dogs that meet the study case definition for a suspect case of leptospirosis seen at participating veterinary clinics and shelters. Participating veterinarians and their veterinary staff collect information by interviewing the dog owner (shelters are an exception as dog will not have an

owner) and reviewing medical and administrative records, as necessary. Basic information about the participating sites will also be collected for study management and to enhance data analysis.

Information will be collected using paper forms and provided in Spanish. Staff at participating sites find it easier to complete a paper copy when abstracting medical record information and interviewing owners for information about their dog's risk factors and symptoms. Study coordinators will enter collected data into an electronic database.

The types of information collected include information about the dog's signalment, location of residence, environmental risk factors, vaccination

history, clinical signs and symptoms, laboratory results, and clinical outcome. Approval of this revision ICR will allow BSPB to continue to collect information which can help inform animal public health and will help contribute to a One Health understanding of leptospirosis in Puerto Rico.

BSPB estimates involvement of at least 411 respondents (a minimum 385 from the general public and 26 veterinarians and their veterinary staff) and estimates a total of 168 hours of burden for research activities each year. The collected information will not impose a cost burden on the respondents beyond that associated with their time to provide the required data.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden (in hours)
Veterinarians or veterinary staff	Enrollment Questionnaire (Attachment C).	26	1	5/60	2
Veterinarians or veterinary staff	Log Sheet (Attachment D)	26	24	1/60	10
Veterinarians or veterinary staff	Case Questionnaire (Attachment E)	26	24	10/60	104
Dog owners (general public)	Case Questionnaire (Attachment E)	624	1	5/60	52
Total	168

Jeffrey M. Zirger,
Acting Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2019-00276 Filed 1-28-19; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group; Cellular and Molecular Biology of Neurodegeneration Study Section.

Date: January 31–February 1, 2019.

Time: 8:30 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Catamaran Hotel, 3999 Mission Boulevard, San Diego, CA 92109.

Contact Person: Laurent Taupenot, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4183, MSC 7850, Bethesda, MD 20892, 301-435-1203, taupenol@csr.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00203 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Advisory Board.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov>).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,

and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Advisory Board.

Date: February 12, 2019.

Open: 1:00 p.m. to 3:15 p.m.

Agenda: Program reports and presentations; business of the Board.

Closed: 3:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Room TE406, Rockville, MD 20850 (Virtual Meeting).

Contact Person: Paulette S. Gray, Ph.D., Executive Secretary, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, Room 7W444, Bethesda, MD 20892, 240-276-6340, grayp@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm>, where an agenda and any additional information for the meeting will be posted when available.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: January 17, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00182 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center For Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group; Surgery, Anesthesiology and Trauma Study Section.

Date: February 6–7, 2019.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Weihua Luo, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5114, MSC 7854, Bethesda, MD 20892, (301) 435-1170, luow@csr.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00178 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Genes, Genomes, and Genetics Integrated Review Group; Molecular Genetics B Study Section.

Date: February 4–5, 2019.

Time: 8:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Michael L. Bloom, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6187, MSC 7804, Bethesda, MD 20892, 301-451-0132, bloomm2@mail.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00180 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group; Neurodifferentiation, Plasticity, Regeneration and Rhythmicity Study Section.

Date: February 5–6, 2019.

Time: 9:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites Alexandria Old Town, 1900 Diagonal Road, Alexandria, VA 22314.

Contact Person: Joanne T. Fujii, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4184, MSC 7850, Bethesda, MD 20892, (301) 435-1178, fujij@csr.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00189 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; "Advancing mAbs to Achieve a Drug-free Sustained HIV Virologic Remission".

Date: February 12, 2019.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Cynthia L. De La Fuente, Ph.D., Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC-9823, Rockville, MD 20852, 240-669-2740, cynthia.delafuente@nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due

to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: January 17, 2019.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00185 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Social Sciences and Population Studies B Study Section.

Date: February 14-15, 2019.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bahia Resort Hotel, 998 West Mission Bay Drive, San Diego, CA 92109.

Contact Person: Kate Fothergill, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3142, Bethesda, MD 20892, 301-435-2309, fothergillke@mail.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 22, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00207 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; AMSC Conflict Review.

Date: February 13, 2019.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892.

Contact Person: Yasuko Furumoto, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, 6701 Democracy Boulevard, Suite 820, Bethesda, MD 20892, 301-827-7835, yasuko.furumoto@nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: January 18, 2019.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00190 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; SBIR Topics 107 and 108.

Date: February 5, 2019.

Time: 11:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7182, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific Review Officer, Office of Scientific Review, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7182, Bethesda, MD 20892, 301-827-7987, Susan.sunnarborg@nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government Shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 17, 2019.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00184 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR16-212: Cognitive Neuroscience and Assessment of Cancer Treatment-Related Cognitive Impairment.

Date: February 6, 2019.

Time: 7:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kristin Kramer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5205, MSC 7846, Bethesda, MD 20892, (301) 437-0911, kramerkm@csr.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00204 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should

notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Drug Abuse.

Date: February 13, 2019.

Closed: 9:00 a.m. to 10:15 a.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Open: 10:30 a.m. to 4:30 p.m.

Agenda: This portion of the meeting will be open to the public for announcements and reports of administrative, legislative, and program developments in the drug abuse field.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, NSC, Room 5274, MSC 9591, Rockville, MD 20892, 301-443-6487, sweiss@nida.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program No.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: January 17, 2019.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00177 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Auditory System Study Section.

Date: February 7–8, 2019.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Renaissance Harborplace Hotel, 202 East Pratt Street, Baltimore, MD 21202.

Contact Person: Brian H. Scott, Ph.D., Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, 301-827-7490, brianscott@mail.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00181 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Improvement of Animal Models for Stem Cell-Based Regenerative Medicine.

Date: February 5, 2019.

Time: 11:30 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Rass M. Shayiq, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2182, MSC 7818, Bethesda, MD 20892, (301) 435-2359, shayiqr@csr.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00186 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Integrative Health Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the ZAT1 SM (46) meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Complementary and Integrative Health Special Emphasis Panel; Mechanisms of Mind and Body Interventions (MMB).

Date: February 1, 2019.

Time: 12:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Martina Schmidt, Ph.D., Chief, Office of Scientific Review, National Center for Complementary & Integrative Health, NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, 301-594-3456, schmidma@mail.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS)

Dated: January 22, 2019.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00193 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Advisory Council.

Date: February 5, 2019.

Open: 8:30 a.m. to 12:00 p.m.

Agenda: To discuss program policies and issues.

Place: National Institutes of Health, Porter Neuroscience Research Center, Building 35A Convent Drive, Bethesda, MD 20892.

Closed: 12:40 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Porter Neuroscience Research Center, Building 35A Convent Drive, Bethesda, MD 20892.

Contact Person: Laura K. Moen, Ph.D., Director, Division of Extramural Research Activities National Heart, Lung, and Blood Institute National Institutes of Health, 6701 Rockledge Drive, Room 7100, Bethesda, MD 20892, 301-435-0260, moenl@mail.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: www.nhlbi.nih.gov/meetings/nhlbac/index.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 18, 2019.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00183 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; Treatment Development—Psychosocial Interventions.

Date: February 7, 2019.

Time: 9:00 a.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: David I. Sommers, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9606, Bethesda, MD 20892, 301-443-7861, dsommers@mail.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: January 18, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00192 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Social Sciences and Population Studies A Study Section.

Date: January 31, 2019.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Edgewater Hotel, 2411 Alaskan Way Pier 67, Seattle, WA 98121.

Contact Person: Suzanne Ryan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3139, MSC 7770, Bethesda, MD 20892, (301) 435-1712, ryansj@csr.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00205 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Collaborative Applications: Behavioral Genetics and Epidemiology.

Date: February 6, 2019.

Time: 8:45 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Melrose Hotel, 2430 Pennsylvania Ave. NW, Washington, DC 20037.

Contact Person: Suzanne Ryan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3139, MSC 7770, Bethesda, MD 20892, (301) 435-1712, ryansj@csr.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00179 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group; Cellular and Molecular Biology of Glia Study Section.

Date: February 7-8, 2019.

Time: 8:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Lorien Hotel & Spa, 1600 King Street, Alexandria, VA 22314.

Contact Person: Linda MacArthur, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4187, Bethesda, MD 20892, 301-537-9986, macarthurlh@csr.nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00187 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Immunology Integrated Review Group; Transplantation, Tolerance, and Tumor Immunology Study Section.

Date: February 4-5, 2019.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Sir Francis Drake Hotel, 450 Powell Street at Sutter, San Francisco, CA 94102.

Contact Person: Jin Huang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4199, MSC 7812, Bethesda, MD 20892, 301-435-1230, jh377p@nih.gov.

This meeting notice is being published less than 15 days in advance of the meeting due to the partial Government shutdown of December 2018.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333,

93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 18, 2019.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-00188 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice To Announce of Requirements and Registration for "Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test" Challenge

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health (NIH) is supplementing and amending a Notice previously published in the **Federal Register** on September 8, 2016 titled "Announcement of Requirements and Registration for "Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test" Challenge." This Notice serves to provide additional details to Step 2 Semi-finalists of the submission requirements and review criteria for Step 3 (Performance Testing in CLIA-certified Laboratories) of this Challenge.

DATES: On or before Monday, November 4, 2019, 11:59 p.m. ET: Step 3 Letter of Intent is due. Only Step 2 Semi-finalists are eligible to submit a Letter of Intent. On or before Friday, January 3, 2020, 5:00 p.m. ET: The submissions from the Step 2 Semi-finalists for Step 3 are due. Submissions received after the deadline of January 3, 2020, at 5:00 p.m. ET will be disqualified and not evaluated by the CLIA-certified laboratories, the Technical Evaluation Panel, or Judging Panel.

Important note: The Step 3 submission must be received by January 3, 2020. Plan to send the submission so it arrives on or before January 3, 2020. In effect, a post-mark date of January 3, 2020, is not sufficient; the submission must be received by that date.

ADDRESSES: The Letter of Intent and Step 3 submission must be submitted to Capital Consulting Corporation no later than the due dates cited above. The letter of intent must be submitted on <http://www.cccinnovationcenter.com/challenges/antimicrobial-resistance-diagnostic-challenge/>.

FOR FURTHER INFORMATION CONTACT: Robert W. Eisinger, Ph.D., NIH, 301-

496–2229 or by email Robert.eisinger@nih.gov.

SUPPLEMENTARY INFORMATION: On September 8, 2016, the National Institutes of Health (NIH) published a Notice in the *Federal Register* titled “Announcement of Requirements and Registration for “Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test” Challenge.” The Notice announced the Antimicrobial Resistance Rapid, Point-of-Need Challenge may result in the awarding of \$20 million dollars for the successful development of new, innovative, accurate, and cost-effective in vitro diagnostic tests that would rapidly inform clinical treatment decisions and be of significant clinical and public health utility to combat the development and spread of antibiotic resistant bacteria and improve antibiotic stewardship. The Notice provided information on submission requirements for Step 3 of the Challenge and indicated that additional details on submission requirements for Step 3 will be made available after the Step 2 Semi-finalists are announced. This Notice serves to provide additional details to Step 2 Semi-finalists of the submission requirements and review criteria for Step 3 (Performance Testing in CLIA-certified Laboratories) of this Challenge.

The NIH is supplementing and amending several components of Step 3 of the Challenge including:

(1) The letter of intent must be submitted by Monday, November 4, 2019, at 11:59 p.m. ET, for all Step 2 Semi-finalists planning to submit for the Step 3 (Performance Testing in CLIA-certified Laboratories) stage of the Challenge. A list of Step 2 Semi-finalists can be found at <http://www.cccinnovationcenter.com/challenges/antimicrobial-resistance-diagnostic-challenge/>.

(2) The Technical Evaluation Panel will use the following 4 criteria for evaluating the Step 3 submissions and the test results from the two CLIA-certified laboratories’ analysis of the Step 3 prototype submissions, including: (a) Innovation; (b) clinical significance; (c) diagnostic performance and feasibility; and (d) sample matrix/setting and ease of use/throughput. These criteria were defined in the September 8, 2016, announcement; however, the announcement incorrectly stated that the Panel will evaluate the in vitro diagnostics (solution) based on six criteria.

(3) Each solution will be tested by two CLIA-certified laboratories against standard FDA-approved in vitro assays using a panel of reference (or well-characterized) pathogens, clinical

specimens, and/or contrived samples to demonstrate usability, stated time to result, appropriate analytical sensitivity/specificity, as well as confirmation of analytical performance (e.g., limit of detection, interference, inclusivity, reproducibility, etc.) reported in the data submitted by the Step 2 Semi-finalist.

(4) Step 2 Semi-finalists will submit:

- a. Sufficient numbers of their diagnostic tests based on the Step 2 solutions for independent testing by both CLIA-certified laboratories, as well as methodology/protocols to perform diagnostic testing using the prototypes. These materials must be received on or before January 3, 2020, at 5:00 p.m. ET by Capital Consulting Corporation, Suite 100, 11821 Parklawn Drive, Rockville, MD 20852. At a future date, the NIH will provide additional information about the specific number of test kits that each Step 2 Semi-finalist will need to provide for CLIA-certified laboratory testing. Submissions received after the deadline of January 3, 2020, at 5:00 p.m. ET will be disqualified and not evaluated by the CLIA-certified laboratories, the Technical Evaluation Panel, or the Judging Panel.

- b. A description sufficiently detailed and organized by sections for evaluation in the technical evaluation and programmatic assessment of the proposed solution in 10 pages or less including the next 8 bullets, 8.5” x 11” inch page, 10-point or greater Arial, Palatino Linotype, or Georgia font and one-inch margins including:

- A title of the proposed solution;
- A one-paragraph executive summary that will be posted on the Challenge website after the “Winners” are announced in July 2020. The Executive Summary must not contain any proprietary information since the website is open to the public;
- A statement as to the source of funds that were used to develop their solution submitted for Step 3 of the Challenge;
- A detailed description of the proposed in vitro diagnostic and the claims of performance using specific types of biospecimens/samples;
- A description of any changes from the original design (Step 2 solution) must be documented and explained;
- One section providing a summary of the data, using the in vitro diagnostic device and the Standard Operating Procedures described in Appendix A, generated with either clinical or contrived samples compared to existing standard techniques demonstrating the performance characteristics (e.g., limits of detection, sensitivity, specificity, and other characteristics that demonstrate

test performance to support detection of biomarkers or analytes). The September 8, 2016, announcement incorrectly stated that diagnostic performance characteristics included positive predictive value and negative predictive value;

- A video not to exceed 15 minutes demonstrating the status of the development and actual use of the device in testing contrived or clinical specimens;

- A section addressing applicable HHS Human Subjects Protections regulations and NIH Inclusion of Women, Children, and Minorities policies, as well as biohazards policies (<https://grants.nih.gov/grants/guide/notice-files?NOT-OD-12-141.html>), if applicable.

(5) An Appendix A with the standard operating procedures for the use of the solution submitted for Step 3 of the Challenge must include all steps to prepare test specimen/sample, perform the assay, and interpret the results.

(6) An Appendix B provide additional data and tables to support the data summary and performance claims based on the use of the proposed solution testing clinical or contrived samples in 5 pages or less.

(7) Each Step 2-Semi-finalist may submit corrections in support of their Step 3 submission within the page limitations cited above as long as Capital Consulting Corporation receives the materials by the deadline of January 3, 2020, at 5:00 p.m. ET. Corrections for Step 3 will not be accepted or evaluated by the CLIA-certified laboratories, Technical Evaluation Panel, or Judging Panel if they are received after January 3, 2020, at 5:00 p.m. ET.

(8) The NIH will perform an initial review of all submissions to ensure they are complete and within the scope of the Challenge. Submissions that are incomplete or outside of the scope of the Challenge will be administratively disqualified and will not be evaluated by the CLIA-certified laboratories, the Technical Evaluation Panel, or the Judging Panel. Disqualified submissions will not be returned to the Step 2 Semi-finalist.

(9) The NIH and Assistant Secretary for Preparedness and Response/ Biomedical Advanced Research and Development Authority may determine that based on the number of submissions received for Step 3 that less competitive submissions will not be discussed by the Technical Evaluation Panel during the Panel’s meeting.

(10) Members of the Technical Evaluation Panel for Step 1 or Step 2 are not eligible to participate in or

contribute to any proposal for Step 3 of the Challenge.

(11) Only Step 2 Semi-finalists are eligible for Step 3 of this Challenge.

(12) All submissions for Step 3 must be in English.

(13) No submissions will be returned to the submitters.

(14) The remainder of the provisions from the September 8, 2016, **Federal Register** Notice (81 FR 62150) not amended here still apply.

Dated: January 11, 2019.

Lawrence A. Tabak,

Deputy Director, National Institutes of Health.

[FR Doc. 2019-00218 Filed 1-28-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

[Docket No. DHS-2018-0076]

Homeland Security Advisory Council

AGENCY: Office of Partnership and Engagement (OPE), Department of Homeland Security (DHS).

ACTION: Notice of open teleconference federal advisory committee meeting; cancellation.

SUMMARY: On December 27, 2018 (83 FR 66724-66725) the Department of Homeland Security (DHS) published a notice announcing that a meeting of the Homeland Security Advisory Council

(HSAC) was to take place on Thursday, January 31, 2019 via teleconference. Due to the lapse in appropriations for the Department of Homeland Security, DHS is cancelling the January 31, 2019 meeting.

FOR FURTHER INFORMATION CONTACT: Mike Miron at HSAC@hq.dhs.gov or 202-447-3135.

SUPPLEMENTARY INFORMATION: None.

Dated: January 23, 2019.

Matthew Hayden,

Deputy Assistant Secretary, Private Sector Office.

[FR Doc. 2019-00258 Filed 1-28-19; 8:45 am]

BILLING CODE 9110-9B-P

Reader Aids

Federal Register

Vol. 84, No. 19

Tuesday, January 29, 2019

CUSTOMER SERVICE AND INFORMATION

Federal Register/Code of Federal Regulations	
General Information, indexes and other finding aids	202-741-6000
Laws	741-6000
Presidential Documents	
Executive orders and proclamations	741-6000
The United States Government Manual	741-6000
Other Services	
Electronic and on-line services (voice)	741-6020
Privacy Act Compilation	741-6050

ELECTRONIC RESEARCH

World Wide Web

Full text of the daily Federal Register, CFR and other publications is located at: www.govinfo.gov. Federal Register information and research tools, including Public Inspection List and electronic text are located at: www.federalregister.gov.

E-mail

FEDREGTOC (Daily Federal Register Table of Contents Electronic Mailing List) is an open e-mail service that provides subscribers with a digital form of the Federal Register Table of Contents. The digital form of the Federal Register Table of Contents includes HTML and PDF links to the full text of each document. To join or leave, go to <https://public.govdelivery.com/accounts/USGPOOFR/subscriber/new>, enter your email address, then follow the instructions to join, leave, or manage your subscription.

PENS (Public Law Electronic Notification Service) is an e-mail service that notifies subscribers of recently enacted laws. To subscribe, go to <http://listserv.gsa.gov/archives/publaws-l.html> and select *Join or leave the list (or change settings)*; then follow the instructions.

FEDREGTOC and **PENS** are mailing lists only. We cannot respond to specific inquiries.

Reference questions. Send questions and comments about the Federal Register system to: fedreg.info@nara.gov. The Federal Register staff cannot interpret specific documents or regulations.

FEDERAL REGISTER PAGES AND DATE, JANUARY

1-30.....	2
31-32.....	3
33-34.....	4
35-64.....	7
65-96.....	8
97-100.....	9
101-102.....	10
103-106.....	11
107-118.....	14
119-120.....	15
121-122.....	16
123-126.....	17
127-194.....	18
195-200.....	22
201-226.....	23
227-360.....	24
361-406.....	25
407-436.....	28
437-466.....	29

CFR PARTS AFFECTED DURING JANUARY

At the end of each month the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

3 CFR	503.....	213
	530.....	213
	570.....	213
Proclamations:		
9834.....	35	578.....213
9835.....	79	579.....213
9836.....	195	801.....213
9837.....	361	825.....213
9838.....	363	1902.....213
9839.....	365	1903.....213
Executive Orders:		
13819 (superseded by		1904.....380
13856).....	65	2560.....213
13855.....	45	2575.....213
13856.....	65	2590.....213
		4022.....123
Administrative Orders:		
Memorandums:		
Memo. of January 15,		30 CFR
2019.....	197	100.....213
Notices:		
Notice of January 16,		34 CFR
2019.....	127	Proposed Rules:
Presidential		106.....409
Determinations:		
No. 2019-07 of		38 CFR
January 16, 2019.....	201	3.....138
No. 2019-08 of		8.....138
January 16, 2019.....	203	14.....138
No. 2019-09 of		17.....407
January 16, 2019.....	205	19.....138
No. 2019-10 of		20.....138
January 16, 2019.....	207	21.....138
10 CFR		
429.....	437	
430.....	437	41 CFR
Proposed Rules:		50-201.....213
430.....	449	
431.....	449	43 CFR
14 CFR		Proposed Rules:
39.....	129, 209, 443	2.....409
19 CFR		
12.....	107, 112	45 CFR
20 CFR		Proposed Rules:
655.....	213	146.....227
702.....	213	147.....227
725.....	213	148.....227
726.....	213	153.....227
21 CFR		155.....227
1308.....	444	156.....227
29 CFR		
5.....	213	50 CFR
500.....	213	622.....407
501.....	213	679.....33, 49, 116, 117, 121,
		124, 367
		Proposed Rules:
		217.....321

LIST OF PUBLIC LAWS

This is the final list of public bills from the Second Session of the 115th Congress which have become Federal laws. This list is also available online at <http://www.archives.gov/federal-register/laws>.

The text of laws is not published in the **Federal Register** but may be ordered in "slip law" (individual pamphlet) form from the Superintendent of Documents, U.S. Government Publishing Office, Washington, DC 20402 (phone, 202-512-1808). The text will also be made available on the Internet from GPO's Federal Digital System (FDsys) at <http://www.gpo.gov/fdsys>. Some laws may not yet be available.

H.R. 1162/P.L. 115-339

No Hero Left Untreated Act (Dec. 21, 2018; 132 Stat. 5036)

H.R. 1210/P.L. 115-340

To designate the facility of the United States Postal Service located at 122 W. Goodwin Street, Pleasanton, Texas, as the "Pleasanton Veterans Post Office". (Dec. 21, 2018; 132 Stat. 5038)

H.R. 1211/P.L. 115-341

To designate the facility of the United States Postal Service located at 400 N. Main Street, Encinal, Texas, as the "Encinal Veterans Post Office". (Dec. 21, 2018; 132 Stat. 5039)

H.R. 1222/P.L. 115-342

Congenital Heart Futures Reauthorization Act of 2017 (Dec. 21, 2018; 132 Stat. 5040)

H.R. 1235/P.L. 115-343

Naismith Memorial Basketball Hall of Fame Commemorative Coin Act (Dec. 21, 2018; 132 Stat. 5043)

H.R. 1318/P.L. 115-344

Preventing Maternal Deaths Act of 2018 (Dec. 21, 2018; 132 Stat. 5047)

H.R. 1733/P.L. 115-345

To direct the Secretary of Energy to review and update a report on the energy and environmental benefits of the re-refining of used lubricating oil. (Dec. 21, 2018; 132 Stat. 5052)

H.R. 1850/P.L. 115-346

To designate the facility of the United States Postal Service

located at 907 Fourth Avenue in Lake Odessa, Michigan, as the "Donna Sauers Besko Post Office". (Dec. 21, 2018; 132 Stat. 5053)

H.R. 3184/P.L. 115-347

To designate the facility of the United States Postal Service located at 180 McCormick Road in Charlottesville, Virginia, as the "Captain Humayun Khan Post Office". (Dec. 21, 2018; 132 Stat. 5054)

H.R. 3342/P.L. 115-348

Sanctioning the Use of Civilians as Defenseless Shields Act (Dec. 21, 2018; 132 Stat. 5055)

H.R. 3383/P.L. 115-349

To designate the flood control project in Sedgwick County, Kansas, commonly known as the Wichita-Valley Center Flood Control Project, as the "M.S. 'Mitch' Mitchell Floodway". (Dec. 21, 2018; 132 Stat. 5059)

H.R. 4032/P.L. 115-350

Gila River Indian Community Federal Rights-of-Way, Easements and Boundary Clarification Act (Dec. 21, 2018; 132 Stat. 5060)

H.R. 4326/P.L. 115-351

To designate the facility of the United States Postal Service located at 200 West North Street in Normal, Illinois, as the "Sgt. Josh Rodgers Post Office". (Dec. 21, 2018; 132 Stat. 5066)

H.R. 4431/P.L. 115-352

Correcting Miscalculations in Veterans' Pensions Act (Dec. 21, 2018; 132 Stat. 5067)

H.R. 4819/P.L. 115-353

Defending Economic Livelihoods and Threatened Animals Act (Dec. 21, 2018; 132 Stat. 5070)

H.R. 5205/P.L. 115-354

To designate the facility of the United States Postal Service located at 701 6th Street in Hawthorne, Nevada, as the "Sergeant Kenneth Eric Bostic Post Office". (Dec. 21, 2018; 132 Stat. 5074)

H.R. 5395/P.L. 115-355

To designate the facility of the United States Postal Service located at 116 Main Street in Dansville, New York, as the "Staff Sergeant Alexandria Gleason-Morrow Post Office Building". (Dec. 21, 2018; 132 Stat. 5075)

H.R. 5412/P.L. 115-356

To designate the facility of the United States Postal Service

located at 25 2nd Avenue in Brentwood, New York, as the "Army Specialist Jose L. Ruiz Post Office Building". (Dec. 21, 2018; 132 Stat. 5076)

H.R. 5475/P.L. 115-357

To designate the facility of the United States Postal Service located at 108 North Macon Street in Bevier, Missouri, as the "SO2 Navy SEAL Adam Olin Smith Post Office". (Dec. 21, 2018; 132 Stat. 5077)

H.R. 5787/P.L. 115-358

Strengthening Coastal Communities Act of 2018 (Dec. 21, 2018; 132 Stat. 5078)

H.R. 5791/P.L. 115-359

To designate the facility of the United States Postal Service located at 9609 South University Boulevard in Highlands Ranch, Colorado, as the "Deputy Sheriff Zackari Spurlock Parrish, III, Post Office Building". (Dec. 21, 2018; 132 Stat. 5082)

H.R. 5792/P.L. 115-360

To designate the facility of the United States Postal Service located at 90 North 4th Avenue in Brighton, Colorado, as the "Detective Heath McDonald Gumm Post Office". (Dec. 21, 2018; 132 Stat. 5083)

H.R. 5923/P.L. 115-361

Walnut Grove Land Exchange Act (Dec. 21, 2018; 132 Stat. 5084)

H.R. 6020/P.L. 115-362

To designate the facility of the United States Postal Service located at 325 South Michigan Avenue in Howell, Michigan, as the "Sergeant Donald Burgett Post Office Building". (Dec. 21, 2018; 132 Stat. 5086)

H.R. 6059/P.L. 115-363

To designate the facility of the United States Postal Service located at 51 Willow Street in Lynn, Massachusetts, as the "Thomas P. Costin, Jr. Post Office Building". (Dec. 21, 2018; 132 Stat. 5087)

H.R. 6160/P.L. 115-364

To amend title 5, United States Code, to clarify the sources of the authority to issue regulations regarding certifications and other criteria applicable to legislative branch employees under Wounded Warriors Federal Leave Act. (Dec. 21, 2018; 132 Stat. 5088)

H.R. 6167/P.L. 115-365

To designate the facility of the United States Postal Service

located at 5707 South Cass Avenue in Westmont, Illinois, as the "James William Robinson Jr. Memorial Post Office Building". (Dec. 21, 2018; 132 Stat. 5089)

H.R. 6216/P.L. 115-366

To designate the facility of the United States Postal Service located at 3025 Woodgate Road in Montrose, Colorado, as the "Sergeant David Kinterknecht Post Office". (Dec. 21, 2018; 132 Stat. 5090)

H.R. 6217/P.L. 115-367

To designate the facility of the United States Postal Service located at 241 N 4th Street in Grand Junction, Colorado, as the "Deputy Sheriff Derek Geer Post Office Building". (Dec. 21, 2018; 132 Stat. 5091)

H.R. 6227/P.L. 115-368

National Quantum Initiative Act (Dec. 21, 2018; 132 Stat. 5092)

H.R. 6335/P.L. 115-369

To designate the facility of the United States Postal Service located at 322 Main Street in Oakville, Connecticut, as the "Oakville Veterans Memorial Post Office". (Dec. 21, 2018; 132 Stat. 5104)

H.R. 6347/P.L. 115-370

7(a) Real Estate Appraisal Harmonization Act (Dec. 21, 2018; 132 Stat. 5105)

H.R. 6348/P.L. 115-371

Small Business Access to Capital and Efficiency Act (Dec. 21, 2018; 132 Stat. 5106)

H.R. 6400/P.L. 115-372

United States Ports of Entry Threat and Operational Review Act (Dec. 21, 2018; 132 Stat. 5107)

H.R. 6405/P.L. 115-373

To designate the facility of the United States Postal Service located at 2801 Mitchell Road in Ceres, California, as the "Lance Corporal Juana Navarro Arellano Post Office Building". (Dec. 21, 2018; 132 Stat. 5110)

H.R. 6428/P.L. 115-374

Frank Leone Post Office Act (Dec. 21, 2018; 132 Stat. 5111)

H.R. 6513/P.L. 115-375

To designate the facility of the United States Postal Service located at 1110 West Market Street in Athens, Alabama, as the "Judge James E. Horton, Jr. Post Office Building". (Dec. 21, 2018; 132 Stat. 5112)

H.R. 6591/P.L. 115–376

To designate the facility of the United States Postal Service located at 501 South Kirkman Road in Orlando, Florida, as the “Napoleon ‘Nap’ Ford Post Office Building”. (Dec. 21, 2018; 132 Stat. 5113)

H.R. 6615/P.L. 115–377

Traumatic Brain Injury Program Reauthorization Act of 2018 (Dec. 21, 2018; 132 Stat. 5114)

H.R. 6621/P.L. 115–378

To designate the facility of the United States Postal Service located at 530 East Main Street in Johnson City, Tennessee, as the “Major Homer L. Pease Post Office”. (Dec. 21, 2018; 132 Stat. 5116)

H.R. 6628/P.L. 115–379

To designate the facility of the United States Postal Service located at 4301 Northeast 4th Street in Renton, Washington, as the “James Marshall ‘Jimi’ Hendrix Post Office Building”. (Dec. 21, 2018; 132 Stat. 5117)

H.R. 6655/P.L. 115–380

To designate the facility of the United States Postal Service located at 44160 State Highway 299 East Suite 1 in McArthur, California, as the “Janet Lucille Oilar Post Office”. (Dec. 21, 2018; 132 Stat. 5118)

H.R. 6780/P.L. 115–381

To designate the facility of the United States Postal Service located at 7521 Paula Drive in Tampa, Florida, as the “Major Andreas O’Keeffe Post Office Building”. (Dec. 21, 2018; 132 Stat. 5119)

H.R. 6831/P.L. 115–382

To designate the facility of the United States Postal Service located at 35 West Main Street in Frisco, Colorado, as the “Patrick E. Mahany, Jr., Post Office Building”. (Dec. 21, 2018; 132 Stat. 5120)

H.R. 6893/P.L. 115–383

Secret Service Overtime Pay Extension Act (Dec. 21, 2018; 132 Stat. 5121)

H.R. 6930/P.L. 115–384

To designate the facility of the United States Postal Service located at 10 Miller Street in Plattsburgh, New York, as the “Ross Bouyea Post Office Building”. (Dec. 21, 2018; 132 Stat. 5122)

H.R. 6964/P.L. 115–385

Juvenile Justice Reform Act of 2018 (Dec. 21, 2018; 132 Stat. 5123)

H.R. 7120/P.L. 115–386

To amend the Federal Election Campaign Act of 1971 to extend through 2023 the authority of the Federal Election Commission to impose civil money penalties on the basis of a schedule of penalties established and published by the Commission. (Dec. 21, 2018; 132 Stat. 5161)

H.R. 7213/P.L. 115–387

Countering Weapons of Mass Destruction Act of 2018 (Dec. 21, 2018; 132 Stat. 5162)

H.R. 7230/P.L. 115–388

To designate the facility of the United States Postal Service located at 226 West Main Street in Lake City, South Carolina, as the “Postmaster Frazier B. Baker Post Office”. (Dec. 21, 2018; 132 Stat. 5171)

H.R. 7243/P.L. 115–389

To amend Public Law 115-217 to change the address of the postal facility designated by such Public Law in honor of Sergeant First Class Alwyn Crendall Cashe, and for other purposes. (Dec. 21, 2018; 132 Stat. 5172)

H.R. 7327/P.L. 115–390

Strengthening and Enhancing Cyber-capabilities by Utilizing Risk Exposure Technology Act (Dec. 21, 2018; 132 Stat. 5173)

S. 756/P.L. 115–391

First Step Act of 2018 (Dec. 21, 2018; 132 Stat. 5194)

S. 1311/P.L. 115–392

Abolish Human Trafficking Act of 2017 (Dec. 21, 2018; 132 Stat. 5250)

S. 1312/P.L. 115–393

Trafficking Victims Protection Act of 2017 (Dec. 21, 2018; 132 Stat. 5265)

S. 2511/P.L. 115–394

Commercial Engagement Through Ocean Technology Act of 2018 (Dec. 21, 2018; 132 Stat. 5281)

S. 3170/P.L. 115–395

CyberTipline Modernization Act of 2018 (Dec. 21, 2018; 132 Stat. 5287)

S. 3628/P.L. 115–396

National Flood Insurance Program Extension Act (Dec. 21, 2018; 132 Stat. 5296)

S. 3749/P.L. 115–397

Congressional Accountability Act of 1995 Reform Act (Dec. 21, 2018; 132 Stat. 5297)

H.R. 767/P.L. 115–398

Stop, Observe, Ask, and Respond to Health and

Wellness Act of 2018 (Dec. 31, 2018; 132 Stat. 5328)

H.R. 2606/P.L. 115–399

Stigler Act Amendments of 2018 (Dec. 31, 2018; 132 Stat. 5331)

H.R. 4227/P.L. 115–400

Vehicular Terrorism Prevention Act of 2018 (Dec. 31, 2018; 132 Stat. 5334)

H.R. 5075/P.L. 115–401

Ashanti Alert Act of 2018 (Dec. 31, 2018; 132 Stat. 5336)

H.R. 5509/P.L. 115–402

Innovations in Mentoring, Training, and Apprenticeships Act (Dec. 31, 2018; 132 Stat. 5343)

S. 7/P.L. 115–403

NASA Enhanced Use Leasing Extension Act of 2018 (Dec. 31, 2018; 132 Stat. 5348)

S. 943/P.L. 115–404

Johnson-O’Malley Supplemental Indian Education Program Modernization Act (Dec. 31, 2018; 132 Stat. 5349)

S. 1520/P.L. 115–405

Modernizing Recreational Fisheries Management Act of 2018 (Dec. 31, 2018; 132 Stat. 5355)

S. 2076/P.L. 115–406

Building Our Largest Dementia Infrastructure for Alzheimer’s Act (Dec. 31, 2018; 132 Stat. 5362)

S. 2248/P.L. 115–407

Veterans Benefits and Transition Act of 2018 (Dec. 31, 2018; 132 Stat. 5368)

S. 2278/P.L. 115–408

State Offices of Rural Health Reauthorization Act of 2018 (Dec. 31, 2018; 132 Stat. 5384)

S. 2736/P.L. 115–409

Asia Reassurance Initiative Act of 2018 (Dec. 31, 2018; 132 Stat. 5387)

S. 3530/P.L. 115–410

Museum and Library Services Act of 2018 (Dec. 31, 2018; 132 Stat. 5412)

H.R. 1660/P.L. 115–411

Global Health Innovation Act of 2017 (Jan. 3, 2019; 132 Stat. 5424)

H.R. 3460/P.L. 115–412

To designate the United States courthouse located at 323 East Chapel Hill Street in Durham, North Carolina, as the “John Hervey Wheeler United States Courthouse”. (Jan. 3, 2019; 132 Stat. 5426)

H.R. 6287/P.L. 115–413

9/11 Memorial Act (Jan. 3, 2019; 132 Stat. 5427)

S. 2276/P.L. 115–414

Good Accounting Obligation in Government Act (Jan. 3, 2019; 132 Stat. 5430)

S. 2652/P.L. 115–415

Stephen Michael Gleason Congressional Gold Medal Act (Jan. 3, 2019; 132 Stat. 5433)

S. 2679/P.L. 115–416

Veterans Small Business Enhancement Act of 2018 (Jan. 3, 2019; 132 Stat. 5436)

S. 2765/P.L. 115–417

RBIC Advisers Relief Act of 2018 (Jan. 3, 2019; 132 Stat. 5438)

S. 2896/P.L. 115–418

Justice Against Corruption on K Street Act of 2018 (Jan. 3, 2019; 132 Stat. 5440)

S. 3031/P.L. 115–419

Federal Personal Property Management Act of 2018 (Jan. 3, 2019; 132 Stat. 5442)

S. 3367/P.L. 115–420

Department of Transportation Reports Harmonization Act (Jan. 3, 2019; 132 Stat. 5444)

S. 3444/P.L. 115–421

To designate the community-based outpatient clinic of the Department of Veterans Affairs in Lake Charles, Louisiana, as the “Douglas Fournet Department of Veterans Affairs Clinic”. (Jan. 3, 2019; 132 Stat. 5449)

S. 3777/P.L. 115–422

Forever GI Bill Housing Payment Fulfillment Act of 2018 (Jan. 3, 2019; 132 Stat. 5450)

S. 2200/P.L. 115–423

National Integrated Drought Information System Reauthorization Act of 2018 (Jan. 7, 2019; 132 Stat. 5454)

S. 2961/P.L. 115–424

Victims of Child Abuse Act Reauthorization Act of 2018 (Jan. 7, 2019; 132 Stat. 5465)

H.R. 2200/P.L. 115–425

Frederick Douglass Trafficking Victims Prevention and Protection Reauthorization Act of 2018 (Jan. 8, 2019; 132 Stat. 5472)

S. 3191/P.L. 115–426

Civil Rights Cold Case Records Collection Act of 2018 (Jan. 8, 2019; 132 Stat. 5489)

S. 1862/P.L. 115–427

Trafficking Victims Protection Reauthorization Act of 2017 (Jan. 9, 2019; 132 Stat. 5503)

S. 3247/P.L. 115-428

Women's Entrepreneurship and Economic Empowerment Act of 2018 (Jan. 9, 2019; 132 Stat. 5509)

H.R. 4689/P.L. 115-429

To authorize early repayment of obligations to the Bureau of Reclamation within the Northport Irrigation District in the State of Nebraska. (Jan. 10, 2019; 132 Stat. 5519)

H.R. 5636/P.L. 115-430

Flatside Wilderness Enhancement Act (Jan. 10, 2019; 132 Stat. 5520)

H.R. 6602/P.L. 115-431

To reauthorize the New Jersey Coastal Heritage Trail Route, and for other purposes. (Jan. 10, 2019; 132 Stat. 5521)

S. 3456/P.L. 115-432

To redesignate Hobe Sound National Wildlife Refuge as the Nathaniel P. Reed Hobe Sound National Wildlife

Refuge, and for other purposes. (Jan. 10, 2019; 132 Stat. 5522)

S. 3661/P.L. 115-433

75th Anniversary of World War II Commemoration Act (Jan. 10, 2019; 132 Stat. 5523)

H.R. 672/P.L. 115-434

Combating European Anti-Semitism Act of 2017 (Jan. 14, 2019; 132 Stat. 5526)

H.R. 4174/P.L. 115-435

Foundations for Evidence-Based Policymaking Act of 2018 (Jan. 14, 2019; 132 Stat. 5529)

H.R. 7279/P.L. 115-436

Water Infrastructure Improvement Act (Jan. 14, 2019; 132 Stat. 5558)

H.R. 7318/P.L. 115-437

To amend the Federal Assets Sale and Transfer Act of 2016 to ensure that the Public Buildings Reform Board has

adequate time to carry out the responsibilities of the Board, and for other purposes. (Jan. 14, 2019; 132 Stat. 5563)

H.R. 7319/P.L. 115-438

To amend the Federal Assets Sale and Transfer Act of 2016 to provide flexibility with respect to the leaseback of certain Federal real property, and for other purposes. (Jan. 14, 2019; 132 Stat. 5564)

S. 512/P.L. 115-439

Nuclear Energy Innovation and Modernization Act (Jan. 14, 2019; 132 Stat. 5565)

S. 1023/P.L. 115-440

Tropical Forest Conservation Reauthorization Act of 2018 (Jan. 14, 2019; 132 Stat. 5580)

S. 1158/P.L. 115-441

Elie Wiesel Genocide and Atrocities Prevention Act of 2018 (Jan. 14, 2019; 132 Stat. 5586)

S. 1580/P.L. 115-442

Protecting Girls' Access to Education in Vulnerable Settings Act (Jan. 14, 2019; 132 Stat. 5590)

Last List December 26, 2018

Public Laws Electronic Notification Service (PENS)

PENS is a free electronic mail notification service of newly enacted public laws. To subscribe, go to <http://listserv.gsa.gov/archives/publaws-l.html>

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service. **PENS** cannot respond to specific inquiries sent to this address.